Toxicology – Toxicant-Induced Seizures

Definition

A seizure is a transient episode of abnormal, excessive neuronal activity that may produce:

• Involuntary motor activity
• Altered or loss of consciousness
• Sensory or behavioral abnormalities
• Autonomic manifestations

In toxicology, seizures are an important manifestation of drug or chemical toxicity and are commonly generalized tonic-clonic.

Prolonged or recurrent seizures can cause severe complications including hypoxia, hyperthermia, metabolic acidosis, rhabdomyolysis, aspiration, brain injury, and death.

Pathophysiology

Toxicants can provoke seizures through several mechanisms, including:

• Reduced inhibitory GABA activity
• Excess excitatory neurotransmission
• Sodium-channel effects
• Excess catecholaminergic activity
• Metabolic abnormalities
• Hypoglycemia
• Hypoxia
• Electrolyte disturbances

Some poisonings produce seizures through a highly specific mechanism.

For example:

Isoniazid → pyridoxine depletion → impaired GABA synthesis → severe seizures

Risk Factors

The likelihood of seizures may be increased by:

• Pre-existing epilepsy
• Previous CNS injury
• Large toxic exposure
• Multiple proconvulsant drugs
• Hypoglycemia
• Hypoxia
• Electrolyte abnormalities
• Withdrawal from alcohol or sedative-hypnotic drugs

A seizure in pregnancy requires urgent evaluation for eclampsia and other obstetric causes, even when toxic exposure is also possible.

Important Toxicologic Causes

Tricyclic Antidepressants

TCA poisoning can produce:

• Seizures
• Altered mental status
• Anticholinergic findings
• Tachycardia
• Hypotension
• QRS widening
• Ventricular dysrhythmias

TCA-associated seizures plus QRS widening strongly suggest clinically important sodium-channel blockade.

Sodium bicarbonate is indicated when significant sodium-channel cardiotoxicity is present.

Bupropion

Bupropion is an important cause of drug-induced seizures.

Features may include:

• Agitation
• Tremor
• Tachycardia
• Seizures
• Altered mental status

Severe poisoning may cause:

• Recurrent seizures
• QRS or QT abnormalities
• Ventricular dysrhythmias
• Cardiogenic shock

Extended-release preparations can produce substantially delayed seizures, so an initially asymptomatic patient may still require prolonged observation after a significant exposure.

Isoniazid

Isoniazid is particularly important because seizures may be:

• Severe
• Recurrent
• Resistant to conventional anticonvulsant therapy

Mechanism:

Isoniazid → functional pyridoxine deficiency → decreased GABA synthesis → seizures

Associated findings may include:

• High-anion-gap metabolic acidosis
• Altered mental status
• Coma

Pyridoxine (vitamin B6) is the specific antidotal therapy.

Theophylline

Theophylline toxicity may produce:

• Nausea/vomiting
• Tremor
• Marked tachycardia
• Hypokalemia
• Hyperglycemia
• Dysrhythmias
• Seizures

Seizures may be severe and difficult to control.

Unlike many poisonings, significant theophylline toxicity may cause seizures without a prolonged warning period.

Stimulants

Examples include:

• Cocaine
• Amphetamines
• Methamphetamine
• Other sympathomimetics

Typical findings include:

• Agitation
• Mydriasis
• Diaphoresis
• Tachycardia
• Hypertension
• Hyperthermia

Severe poisoning may progress to:

• Seizures
• Dysrhythmias
• Rhabdomyolysis
• Metabolic acidosis
• Cardiovascular collapse

Antihistamines and Anticholinergic Drugs

First-generation antihistamines and other antimuscarinic agents can produce:

• Agitated delirium
• Mydriasis
• Dry mucous membranes
• Tachycardia
• Urinary retention
• Reduced bowel sounds
• Hyperthermia
• Seizures

Some antihistamines, particularly in severe overdose, can also produce sodium-channel blockade with QRS widening.

Camphor

Camphor exposure is an important cause of rapid-onset seizures, particularly in young children.

Manifestations may include:

• Nausea/vomiting
• Agitation
• Confusion
• Seizures

Neurologic toxicity can develop rapidly.

Lithium

Severe lithium toxicity may produce:

• Coarse tremor
• Hyperreflexia
• Myoclonus
• Ataxia
• Confusion
• Seizures
• Coma

Neurologic toxicity is particularly important in chronic or acute-on-chronic poisoning.

Severe cases may require hemodialysis.

Chloroquine and Hydroxychloroquine

Severe poisoning may cause rapid:

• Seizures
• Hypotension
• Hypokalemia
• QRS widening
• Ventricular dysrhythmias
• Cardiovascular collapse

Neurologic and cardiovascular deterioration can occur quickly.

Local Anesthetic Systemic Toxicity

Systemic local anesthetic toxicity may initially cause neurologic symptoms such as:

• Perioral numbness
• Metallic taste
• Tinnitus
• Agitation
• Tremor

This can progress to:

• Seizures
• CNS depression
• Dysrhythmias
• Cardiovascular collapse

Intravenous lipid emulsion is an important therapy for severe local anesthetic systemic toxicity, particularly when cardiovascular toxicity develops.

Carbon Monoxide

Severe carbon monoxide poisoning can cause:

• Headache
• Nausea
• Dizziness
• Confusion
• Syncope
• Seizures
• Coma

Multiple people developing similar symptoms in the same environment is an important clue.

A normal conventional pulse oximetry reading does not exclude carbon monoxide poisoning.

Hypoglycemic Agents

Insulin and insulin-secretagogue medications can cause neuroglycopenia.

Clinical findings include:

• Sweating
• Confusion
• Behavioral abnormalities
• Weakness
• Seizures
• Coma

Blood glucose should be checked immediately in any patient with an unexplained seizure.

Organophosphate and Carbamate Poisoning

Severe cholinergic poisoning may cause seizures.

Associated findings include:

• Miosis
• Salivation
• Lacrimation
• Bronchorrhea
• Bronchospasm
• Vomiting
• Diarrhea
• Sweating
• Bradycardia
• Fasciculations
• Weakness

Seizures may accompany severe CNS toxicity.

Treatment of significant organophosphate poisoning includes:

• Airway and ventilatory support
• Atropine
• Pralidoxime
• Benzodiazepines for seizures

Salicylates

Seizures are a late and concerning manifestation of severe salicylate poisoning.

Other findings include:

• Tachypnea
• Tinnitus
• Nausea/vomiting
• Diaphoresis
• Respiratory alkalosis
• High-anion-gap metabolic acidosis
• Hyperthermia
• Altered mental status

Seizures suggest severe toxicity and may accompany worsening CNS dysfunction.

Withdrawal Syndromes

Withdrawal from CNS depressants can provoke seizures.

Important causes include:

• Ethanol withdrawal
• Benzodiazepine withdrawal
• Barbiturate withdrawal

Associated findings may include:

• Tremor
• Agitation
• Tachycardia
• Hypertension
• Diaphoresis
• Hallucinations
• Hyperthermia

Benzodiazepines are central to treatment of severe alcohol or sedative-hypnotic withdrawal.

Strychnine: An Important Seizure Mimic

Strychnine causes severe painful muscular spasms rather than true epileptic seizures.

Typical findings include:

• Stimulus-induced muscle spasms
• Generalized rigidity
• Opisthotonus
• Preserved consciousness between or during early spasms

This distinction can help differentiate strychnine poisoning from generalized tonic-clonic seizures.

Nontoxicologic Differential Diagnosis

Not every seizure in a poisoned or potentially poisoned patient is caused by a toxicant.

Important alternative causes include:

Metabolic

• Hypoglycemia
• Hyponatremia
• Hypocalcemia
• Hypomagnesemia
• Uremia
• Hypoxia

Structural CNS Disease

• Intracranial hemorrhage
• Ischemic stroke
• Traumatic brain injury
• Brain tumor
• Cerebral edema

Infection

• Meningitis
• Encephalitis
• Brain abscess

Other

• Epilepsy
• Eclampsia
• Alcohol/sedative withdrawal

Psychogenic nonepileptic seizures can also mimic epilepsy, but should not be diagnosed merely from one historical or examination feature; video-EEG confirmation is the diagnostic standard when uncertainty persists.

Clinical Clues to the Toxicant

Tachycardia + Hypertension + Hyperthermia

Consider:

• Cocaine
• Amphetamines
• Other sympathomimetics
• MAOI toxicity
• Serotonin syndrome
• Severe withdrawal

Tachycardia + Hypotension

Consider:

• TCA poisoning
• Theophylline
• Chloroquine/hydroxychloroquine
• Other severe cardiotoxic poisoning

Bradycardia + Hypotension

Consider:

• Beta-blockers
• Organophosphates
• Carbamates
• Other cardiodepressant agents

Dry Skin + Mydriasis + Tachycardia

Suggests an anticholinergic toxidrome.

Potential causes include:

• First-generation antihistamines
• Antimuscarinic medications
• TCAs

Miosis + Secretions

Miosis accompanied by:

• Salivation
• Bronchorrhea
• Diarrhea
• Sweating
• Fasciculations

strongly suggests a cholinergic syndrome.

Nystagmus

May occur with:

• PCP
• Carbamazepine
• Certain anticonvulsants
• Sedative/intoxicating agents

Rigidity + Hyperthermia

Consider:

• Serotonin syndrome
• Neuroleptic malignant syndrome
• MAOI-related toxicity
• Malignant hyperthermia in the appropriate peri-anesthetic setting

Clonus and hyperreflexia favor serotonin syndrome.

Severe generalized rigidity with a slower onset favors NMS.

Complications of Prolonged Seizures

Prolonged or recurrent seizures can produce:

• Hypoxemia
• Hypercapnia
• Lactic acidosis
• Hyperthermia
• Rhabdomyolysis
• Hyperkalemia
• Acute kidney injury
• Aspiration
• Brain injury
• Cardiovascular instability

A transient lactate elevation and high-anion-gap metabolic acidosis can occur after a generalized tonic-clonic seizure and often improve as the seizure-related lactate clears.

Persistent severe acidosis should prompt investigation for another cause.

Initial Evaluation

Immediate priorities are:

Airway → breathing → circulation → stop seizure → identify reversible causes

Assess:

• Airway protection
• Ventilation
• Oxygenation
• Heart rate and rhythm
• Blood pressure
• Temperature
• Neurologic status

Obtain a rapid bedside glucose immediately.

Laboratory Evaluation

Important investigations may include:

• Glucose
• Electrolytes
• Calcium
• Magnesium
• Bicarbonate
• BUN and creatinine
• Blood gas
• Lactate
• CK

Depending on the exposure, obtain targeted testing such as:

• Salicylate concentration
• Acetaminophen concentration
• Lithium concentration
• Theophylline concentration
• Carbon monoxide testing
• Anticonvulsant concentrations

Broad urine drug screens have important limitations and should not replace toxidrome-based assessment.

ECG

An ECG is essential when toxicant-induced seizure is suspected.

Look for:

• QRS widening
• QT prolongation
• Bradycardia
• AV block
• Ventricular dysrhythmias

Seizure + QRS widening should particularly raise concern for a sodium-channel-blocking drug such as a TCA or certain antihistamines.

Neuroimaging and Lumbar Puncture

Head CT or other neuroimaging should be considered when there is concern for:

• Trauma
• Intracranial hemorrhage
• Focal neurologic deficit
• Structural CNS disease
• Unexplained persistent altered mental status

Lumbar puncture may be required when CNS infection or another appropriate neurologic diagnosis is suspected.

Management of Toxicant-Induced Seizures

First-Line: Benzodiazepines

Benzodiazepines are the preferred initial treatment for most toxicant-induced seizures.

They enhance GABA-mediated inhibition and are particularly useful because many toxic seizures result from excessive CNS excitation.

Examples include:

• Lorazepam
• Diazepam
• Midazolam

Repeated treatment may be necessary for recurrent seizures.

Persistent or Refractory Seizures

If seizures continue despite adequate benzodiazepine therapy, escalation may include:

• Additional GABAergic antiseizure therapy
• Airway control and mechanical ventilation when necessary
• Continuous EEG monitoring
• Specialist toxicology and critical-care management

Phenobarbital is an important second-line option for many toxin-induced refractory seizures.

Severe refractory status epilepticus may require anesthetic therapy in an ICU.

Role of Phenytoin

Phenytoin is generally less useful for many toxicant-induced seizures because it does not correct the mechanisms responsible for many poison-induced convulsions.

In particular, it should not be considered the preferred treatment for seizures caused by:

• Isoniazid
• Theophylline
• Withdrawal
• Many stimulant poisonings

Treatment should instead emphasize benzodiazepines and toxin-specific therapy.

Isoniazid-Induced Seizures

Isoniazid poisoning is a major exception requiring specific antidotal therapy.

Pyridoxine (vitamin B6) should be administered when isoniazid toxicity is strongly suspected, particularly with refractory seizures.

Benzodiazepines are used concurrently.

Failure to recognize isoniazid toxicity can result in persistent seizures despite conventional anticonvulsant therapy.

Neuromuscular Paralysis

Neuromuscular blocking agents may stop visible muscular activity but do not stop cerebral seizure activity.

Therefore, if paralysis is required for airway management or severe refractory convulsive activity:

Continuous EEG monitoring is important when ongoing seizure activity remains possible.

Paralysis must never be mistaken for successful treatment of the underlying seizure.

Airway Management

Endotracheal intubation may be necessary when there is:

• Persistent status epilepticus
• Severe respiratory depression
• Recurrent seizures with inadequate ventilation
• Severe aspiration risk
• Inability to protect the airway
• Need for deep sedation or anesthetic therapy

Airway management should occur alongside treatment of the seizure rather than delaying anticonvulsant therapy.

Decontamination

Do not induce vomiting.

Routine gastric lavage is generally not recommended.

Activated charcoal may be considered only in selected recent, serious, adsorbable ingestions when the airway is adequately protected.

A patient who is actively seizing or has markedly impaired consciousness has a major aspiration risk, so gastrointestinal decontamination should never take priority over stabilization.

Monitoring

Patients with significant toxicant-induced seizures should be monitored for:

• Recurrent seizures
• Respiratory depression
• Oxygenation and ventilation
• Dysrhythmias
• Hypotension
• Hyperthermia
• Rhabdomyolysis
• Electrolyte abnormalities
• Acute kidney injury

Continuous cardiac monitoring is appropriate in significant poisoning.

Continuous EEG may be required for refractory seizures, persistent unexplained coma, or patients receiving neuromuscular blockade.

Key Points

• Toxicant-induced seizures are commonly generalized tonic-clonic seizures.
• Important mechanisms include reduced GABA activity, excessive excitatory neurotransmission, metabolic abnormalities, hypoglycemia, and hypoxia.
• Common toxicologic causes include bupropion, TCAs, antihistamines, stimulants, isoniazid, theophylline, lithium, camphor, salicylates, and withdrawal syndromes.
• Always check bedside glucose immediately in an unexplained seizure.
• Obtain an ECG, because seizures may accompany life-threatening cardiotoxic poisoning.
• Seizure + QRS widening suggests possible sodium-channel-blocker toxicity.
• Isoniazid should be considered when seizures are unusually refractory, especially with compatible exposure history and metabolic acidosis.
• Pyridoxine is the specific antidotal therapy for isoniazid-induced seizures.
• Benzodiazepines are first-line treatment for most toxicant-induced seizures.
• Phenobarbital or other GABAergic therapy may be required for refractory seizures.
• Phenytoin is generally less effective for many toxin-induced seizures and is not the preferred universal second-line therapy.
• Neuromuscular paralysis eliminates visible convulsions but does not terminate cerebral seizure activity.
• Prolonged seizures can cause hyperthermia, lactic acidosis, rhabdomyolysis, hypoxia, aspiration, and brain injury.
• Always evaluate for nontoxicologic causes, including metabolic abnormalities, CNS infection, structural brain disease, epilepsy, and eclampsia.

Toxicology – Pulmonary Edema

Definition

Pulmonary edema is the abnormal accumulation of fluid within the pulmonary interstitium and alveolar spaces.

As fluid accumulates, it interferes with:

• Oxygen diffusion
• Alveolar ventilation
• Lung compliance
• Normal gas exchange

Progressive pulmonary edema can therefore cause hypoxemia and acute respiratory failure.

Classification

Pulmonary edema is broadly divided into:

• Cardiogenic pulmonary edema
• Noncardiogenic pulmonary edema

Most toxicologic causes are noncardiogenic, although toxins that cause severe myocardial depression can produce cardiogenic edema.

Cardiogenic Pulmonary Edema

Cardiogenic pulmonary edema results from elevated pulmonary hydrostatic pressure, usually secondary to left-sided cardiac dysfunction.

Typical sequence:

Left ventricular dysfunction → increased left atrial pressure → increased pulmonary venous/capillary pressure → fluid movement into interstitium and alveoli

Potential mechanisms include:

• Impaired LV systolic function
• Severe diastolic dysfunction
• Acute valvular dysfunction
• Myocardial ischemia
• Severe hypertension
• Toxin-induced myocardial depression

Noncardiogenic Pulmonary Edema

Noncardiogenic pulmonary edema results primarily from increased permeability of the alveolar-capillary barrier, rather than elevated left-sided cardiac pressure.

This may occur following:

• Direct inhalational lung injury
• Aspiration
• Severe systemic poisoning
• Systemic inflammatory response
• Acute respiratory distress syndrome (ARDS)

Mechanism:

Alveolar-capillary injury → increased permeability → protein-rich fluid enters interstitium/alveoli → impaired gas exchange

Toxicologic Causes

Opioids

Opioid poisoning may be associated with noncardiogenic pulmonary edema.

Typical opioid findings include:

• CNS depression
• Bradypnea
• Hypoventilation
• Miosis

Pulmonary edema may manifest with:

• Hypoxemia
• Crackles
• Frothy airway secretions
• Bilateral pulmonary infiltrates

The immediate priority remains restoration of adequate ventilation.

Naloxone reverses opioid-induced respiratory depression, but pulmonary edema may occasionally be recognized or develop around the time of reversal; this should not prevent appropriate naloxone use when ventilation is impaired.

Salicylates

Severe salicylate poisoning can cause noncardiogenic pulmonary edema, particularly in older adults and patients with significant systemic toxicity.

Associated findings include:

• Tachypnea
• Tinnitus
• Nausea/vomiting
• Diaphoresis
• Respiratory alkalosis
• High-anion-gap metabolic acidosis
• Altered mental status

Pulmonary edema in salicylate poisoning indicates potentially severe toxicity.

Stimulants

Cocaine and amphetamine-type stimulants can produce pulmonary complications.

Associated systemic findings may include:

• Agitation
• Tachycardia
• Hypertension
• Hyperthermia
• Seizures
• Dysrhythmias

Pulmonary injury may result from several mechanisms, including direct lung injury, inflammation, ischemia, aspiration, or cardiac dysfunction.

Hydrocarbon Aspiration

Aspiration of low-viscosity hydrocarbons can produce chemical pneumonitis and potentially severe pulmonary injury.

Clinical progression may include:

Aspiration → coughing/choking → inflammatory lung injury → worsening hypoxemia

Findings include:

• Persistent cough
• Tachypnea
• Dyspnea
• Hypoxemia
• Fever
• Crackles

Pulmonary abnormalities can worsen over several hours.

Irritant Gas Inhalation

Important inhaled pulmonary toxicants include:

• Chlorine
• Chloramine
• Ammonia
• Phosgene
• Nitrogen dioxide
• Ozone
• Hydrogen chloride
• Acrolein
• Isocyanates
• Smoke products

These substances can injure the respiratory epithelium and alveolar-capillary membrane.

Water Solubility and Symptom Timing

Highly water-soluble gases tend to cause early upper-airway and mucosal irritation.

Examples include:

• Ammonia
• Hydrogen chloride

Poorly water-soluble gases can penetrate more deeply into the lungs and may produce delayed pulmonary injury.

Classic examples include:

• Phosgene
• Nitrogen dioxide

Therefore:

An initially reassuring examination does not always exclude serious inhalational lung injury.

Phosgene

Phosgene is a classic cause of delayed noncardiogenic pulmonary edema.

Early symptoms may be relatively mild:

• Cough
• Throat irritation
• Chest discomfort

After a latent period, patients may develop:

• Increasing dyspnea
• Tachypnea
• Hypoxemia
• Crackles
• Pulmonary edema

Delayed deterioration is an important diagnostic feature.

Organophosphate and Carbamate Poisoning

These poisonings can cause severe respiratory compromise, but pulmonary secretions should be distinguished from true pulmonary edema.

Muscarinic excess produces:

• Bronchorrhea
• Bronchospasm
• Salivation
• Lacrimation
• Miosis
• Vomiting
• Diarrhea
• Bradycardia

Nicotinic toxicity may produce:

• Fasciculations
• Weakness
• Respiratory muscle paralysis

Respiratory failure may therefore result from a combination of:

Bronchorrhea + bronchospasm + respiratory muscle weakness + CNS effects

Tricyclic Antidepressants

Severe TCA poisoning can occasionally be complicated by pulmonary edema.

More characteristic manifestations include:

• Altered mental status
• Anticholinergic findings
• Seizures
• QRS widening
• Hypotension
• Ventricular dysrhythmias

Cardiovascular instability results primarily from sodium-channel blockade and myocardial toxicity.

Cardiotoxic Drugs

Beta-Blockers and Calcium Channel Blockers

Severe poisoning can produce:

• Bradycardia
• AV block
• Myocardial depression
• Hypotension
• Cardiogenic shock

Marked myocardial dysfunction may consequently cause cardiogenic pulmonary edema.

Colchicine

Severe colchicine poisoning causes multisystem toxicity.

Early manifestations often include:

• Nausea
• Vomiting
• Abdominal pain
• Diarrhea

Severe poisoning may progress to:

• Myocardial dysfunction
• Shock
• Respiratory failure
• Multiorgan failure

Pulmonary edema may occur as part of severe cardiopulmonary toxicity.

Other Causes

Important nontoxicologic causes include:

• Acute heart failure
• Myocardial infarction
• Cardiomyopathy
• Myocarditis
• Severe hypertension
• Acute valvular disease
• Sepsis
• Severe trauma
• Burns
• Aspiration of gastric contents
• ARDS

These conditions should remain in the differential even when poisoning is suspected.

Clinical Features

The primary consequence of pulmonary edema is impaired oxygenation.

Common manifestations include:

• Dyspnea
• Tachypnea
• Increased work of breathing
• Cough
• Hypoxemia
• Chest discomfort
• Orthopnea, particularly in cardiogenic edema
• Restlessness or anxiety

Severe disease may produce:

• Cyanosis
• Frothy sputum
• Respiratory fatigue
• Hypercapnia
• Altered mental status
• Respiratory failure

Pulmonary Examination

Early disease may present with only:

• Tachypnea
• Mild hypoxemia

As pulmonary fluid increases:

• Crackles may develop.
• Wheezing may occur.
• Breath sounds may become abnormal.
• Work of breathing increases.

Auscultatory findings alone do not reliably distinguish cardiogenic from noncardiogenic edema.

Cardiogenic Clinical Clues

Features supporting cardiogenic pulmonary edema include:

• Known cardiac disease
• Elevated jugular venous pressure
• Peripheral edema
• S3 gallop
• Orthopnea
• Evidence of myocardial dysfunction
• Cardiomegaly
• Pleural effusions

However, none of these findings alone is completely diagnostic.

Noncardiogenic Clinical Clues

Noncardiogenic edema is more likely when there is:

• A compatible toxic exposure
• Aspiration
• Sepsis or systemic inflammation
• Inhalational injury
• Bilateral pulmonary infiltrates without clear evidence of left-sided heart failure

Modern evaluation often uses bedside echocardiography and lung ultrasound together with the overall clinical picture.

Diagnostic Evaluation

Pulse Oximetry

Pulse oximetry provides continuous assessment of oxygen saturation.

Persistent or worsening hypoxemia indicates significant pulmonary dysfunction.

However, pulse oximetry does not measure ventilation and may not identify hypercapnia.

Blood Gas Analysis

Blood gas testing may be useful in severe respiratory distress.

Possible findings include:

• Hypoxemia
• Hypercapnia with ventilatory failure
• Respiratory alkalosis early in some conditions
• Metabolic acidosis from the underlying poisoning

Chest Imaging

Chest radiography can support the diagnosis but may be normal early, particularly after certain inhalational exposures.

Cardiogenic Edema

Possible findings include:

• Bilateral perihilar opacities
• Vascular redistribution
• Interstitial edema
• Kerley B lines
• Cardiomegaly
• Pleural effusions

Noncardiogenic Edema

Possible findings include:

• Bilateral diffuse or patchy opacities
• Alveolar infiltrates
• Normal cardiac silhouette

Imaging findings overlap considerably, so chest radiography should not be interpreted in isolation.

Bedside Ultrasound

Lung ultrasound may demonstrate diffuse B-lines, supporting the presence of interstitial/alveolar fluid.

Focused cardiac ultrasound can assess:

• Ventricular function
• Gross volume status
• Pericardial abnormalities
• Evidence supporting cardiogenic shock

This is often more practical than invasive hemodynamic monitoring.

ECG

An ECG is particularly important when pulmonary edema may result from:

• Myocardial ischemia
• TCA poisoning
• Beta-blocker poisoning
• Calcium channel blocker poisoning
• Stimulant toxicity
• Other cardiotoxic agents

Evaluate for:

• Ischemia
• Bradycardia
• AV block
• QRS widening
• QT abnormalities
• Dysrhythmias

Laboratory Evaluation

Testing should be directed toward the suspected cause.

Possible investigations include:

• Electrolytes
• Glucose
• Renal function
• Blood gas
• Lactate
• Cardiac biomarkers when indicated
• CBC
• CK when rhabdomyolysis is suspected

Targeted toxicology testing may include:

• Salicylate concentration
• Acetaminophen concentration when relevant
• Specific drug concentrations when clinically useful

Broad urine drug screening has important limitations and should not replace clinical assessment.

Management

The major priorities are:

Correct hypoxemia → support ventilation → identify and treat the underlying toxicant

Management depends on the severity and mechanism of pulmonary edema.

Airway and Oxygenation

Provide supplemental oxygen when hypoxemia is present.

Patients with significant respiratory distress may benefit from positive-pressure ventilatory support, depending on clinical circumstances.

Endotracheal intubation and mechanical ventilation may be necessary when there is:

• Severe refractory hypoxemia
• Progressive respiratory fatigue
• Inadequate ventilation
• Severe CNS depression
• Inability to protect the airway

Fluid Management

Fluid administration should be individualized.

Excessive IV fluid can worsen pulmonary edema.

However, toxicologic patients may simultaneously have:

• Hypotension
• Vasodilation
• Dehydration
• Cardiogenic shock

Therefore, hypotension should not automatically trigger large-volume fluid administration.

When fluids are appropriate, use careful reassessment after limited administration.

Persistent shock may require early vasopressor therapy and treatment of the specific poisoning.

Cardiogenic Pulmonary Edema

Treatment should address the underlying cardiac problem.

Depending on blood pressure and volume status, therapy may include:

• Oxygen/ventilatory support
• Positive-pressure ventilation
• Nitrates when appropriate
• Diuretics when volume overload is present
• Treatment of myocardial ischemia
• Treatment of dysrhythmias
• Toxin-specific cardiovascular therapy

The older routine use of morphine for cardiogenic pulmonary edema is no longer recommended because benefit has not been established and respiratory depression or hypotension may occur.

Noncardiogenic Pulmonary Edema

Management is primarily supportive and directed toward the cause.

Possible interventions include:

• Oxygen
• Appropriate positive-pressure ventilation
• Lung-protective mechanical ventilation when ARDS develops
• Careful fluid management
• Treatment of the causative poisoning
• Treatment of associated shock

Routine diuresis is not automatically indicated simply because pulmonary edema is present; volume status and mechanism should guide therapy.

Toxin-Specific Treatment

Examples include:

• Opioids → naloxone when respiratory depression is present
• Salicylates → alkalinization and hemodialysis when indicated
• TCA sodium-channel toxicity → sodium bicarbonate
• Organophosphates → atropine + pralidoxime when indicated
• Beta-blocker/CCB toxicity → toxin-specific cardiovascular support

The pulmonary edema itself does not replace treatment of the underlying poisoning.

Decontamination

Induced vomiting is not recommended.

Routine gastric lavage is generally not recommended, particularly in patients with:

• Respiratory distress
• Altered mental status
• Aspiration risk
• Unprotected airway

Activated charcoal may be considered only for selected recent, serious, adsorbable ingestions when the airway is adequately protected.

In pulmonary edema, preventing further aspiration is especially important.

Monitoring

Patients with clinically significant pulmonary edema require close monitoring of:

• Respiratory rate
• Work of breathing
• Oxygen saturation
• Mental status
• Blood pressure
• Heart rate and rhythm
• Urine output when critically ill

Serial evaluation may include:

• Blood gases
• Electrolytes
• Renal function
• Chest imaging
• Bedside ultrasound

Delayed Pulmonary Edema

Some inhaled toxicants can cause significant pulmonary injury hours after exposure.

Particularly important examples include:

• Phosgene
• Nitrogen dioxide
• Certain other poorly water-soluble irritant gases

Therefore:

Normal initial examination or chest radiograph does not always exclude later respiratory deterioration.

Observation should be based on the specific exposure and clinical findings.

Prognosis

Outcome depends primarily on:

• Underlying toxicant
• Severity of hypoxemia
• Degree of lung injury
• Cardiovascular involvement
• Duration before treatment
• Development of ARDS or multiorgan failure

Many toxicologic causes improve with appropriate supportive and toxin-specific treatment.

Severe lung injury can result in prolonged respiratory failure and, occasionally, persistent pulmonary dysfunction.

Key Points

• Pulmonary edema is fluid accumulation within the pulmonary interstitium and alveoli, causing impaired gas exchange.
• It is classified as cardiogenic or noncardiogenic.
• Cardiogenic edema results primarily from increased pulmonary hydrostatic pressure.
• Noncardiogenic edema results primarily from increased alveolar-capillary permeability.
• Most toxicologic causes are noncardiogenic.
• Important toxicologic causes include opioids, salicylates, stimulants, hydrocarbon aspiration, irritant gases, and severe systemic poisonings.
• Beta-blockers, calcium channel blockers, and other cardiotoxic agents may cause cardiogenic pulmonary edema through myocardial depression.
• Organophosphate poisoning causes prominent bronchorrhea and respiratory muscle dysfunction, which may mimic or coexist with pulmonary edema.
• Phosgene and other poorly water-soluble inhalants may cause delayed pulmonary injury.
• Chest radiography can be normal early.
• Management prioritizes oxygenation, ventilation, careful fluid management, and treatment of the underlying poisoning.
• Routine morphine is not recommended for cardiogenic pulmonary edema.
• Diuretics are appropriate when clinically indicated by cardiogenic congestion or volume overload, but are not routine therapy for all toxicologic pulmonary edema.
• Excessive IV fluid administration can worsen pulmonary edema.
• Significant respiratory failure may require positive-pressure ventilation or endotracheal intubation.

Toxicology – Peripheral Neuropathy

Definition

Peripheral neuropathy is dysfunction or injury involving the peripheral nervous system, producing abnormalities of:

• Sensory function
• Motor function
• Autonomic function

Toxic peripheral neuropathies are commonly symmetric polyneuropathies affecting the distal extremities first.

A typical pattern is:

Distal sensory symptoms → progressive proximal involvement → possible motor weakness and reflex loss

Clinical Pattern

Sensory Symptoms

Sensory abnormalities commonly include:

• Tingling
• Prickling
• Burning
• Numbness
• Stinging sensations
• Neuropathic pain
• Reduced sensation

Symptoms usually begin distally in the feet and toes, although some toxic neuropathies may initially involve the hands.

As the neuropathy progresses, symptoms extend proximally.

The classic distribution is described as:

“Stocking-glove” sensory loss

Lower-extremity involvement usually becomes more prominent than upper-extremity involvement.

Motor Symptoms

Motor neuropathy may produce:

• Distal weakness
• Difficulty walking
• Foot drop
• Wrist drop
• Reduced grip strength
• Muscle wasting in chronic cases

Weakness commonly progresses:

Distal → proximal

Deep tendon reflexes may become reduced and severe polyneuropathy can produce generalized areflexia.

Autonomic Neuropathy

Peripheral autonomic nerve involvement can produce:

• Orthostatic hypotension
• Abnormal sweating
• Gastrointestinal dysmotility
• Urinary dysfunction
• Sexual dysfunction
• Abnormal heart-rate responses

Autonomic abnormalities may accompany sensory or motor neuropathy depending on the underlying toxicant.

Pathophysiologic Classification

Toxic neuropathies can be classified according to the portion of the peripheral nerve that is primarily injured.

Axonopathy

Axonopathy refers to damage primarily involving the nerve axon.

It is one of the most common patterns of toxic peripheral neuropathy.

Long axons are particularly vulnerable, producing a length-dependent neuropathy.

Therefore:

Longest nerves affected first → feet before hands → distal before proximal

Recovery can be slow because damaged axons must regenerate.

Neuronopathy

Neuronopathy involves injury to the nerve-cell body.

Depending on the affected neurons, injury may involve:

• Anterior horn cells → motor dysfunction
• Dorsal root ganglia → sensory dysfunction
• Autonomic neurons → autonomic dysfunction

Sensory neuronopathy may produce a pattern that is less strictly length-dependent than typical distal axonopathy.

Myelinopathy

Myelinopathy results from injury to the myelin sheath surrounding peripheral nerves.

Large myelinated fibers may be particularly affected.

Clinical manifestations can include impaired:

• Vibration sensation
• Proprioception
• Light touch
• Motor conduction
• Reflexes

Electrodiagnostic testing can help distinguish demyelination from primary axonal injury.

Mononeuropathy

Mononeuropathy involves one individual peripheral nerve.

Examples include isolated dysfunction of the:

• Median nerve
• Ulnar nerve
• Radial nerve
• Peroneal nerve

Compression and traumatic injury are common nontoxic causes.

Polyneuropathy

Polyneuropathy involves multiple peripheral nerves.

Most toxic neuropathies are:

• Diffuse
• Bilateral
• Relatively symmetric
• Distal-predominant

This pattern is an important clue to systemic toxic, metabolic, nutritional, or medication-related disease.

Toxic Causes of Predominantly Sensory Neuropathy

Important agents include:

• Cisplatin
• Taxanes
• Pyridoxine excess
• Nitrous oxide
• Colchicine
• Some antiretroviral medications
• Selected antimicrobial agents

Symptoms may include:

• Paresthesias
• Numbness
• Burning pain
• Loss of vibration
• Impaired proprioception

Nitrous Oxide

Repeated or substantial nitrous oxide exposure can produce neurologic dysfunction by functionally inactivating vitamin B12.

This interferes with methionine synthase and normal myelin metabolism.

Clinical manifestations may include:

• Paresthesias
• Sensory loss
• Gait abnormalities
• Weakness
• Impaired proprioception
• Ataxia

Neurologic toxicity can occur even when the measured serum vitamin B12 concentration is not dramatically reduced.

Toxic Causes of Combined Sensory and Motor Neuropathy

Important causes include:

• Arsenic
• Thallium
• Lead
• Chronic ethanol exposure
• Isoniazid
• Metronidazole
• Nitrofurantoin
• Phenytoin
• Vincristine
• Carbon disulfide
• Acrylamide
• n-Hexane
• Certain organophosphates
• Amiodarone

The exact pattern depends on the toxicant and duration of exposure.

Arsenic

Acute or chronic arsenic exposure can produce a painful sensorimotor peripheral neuropathy.

Neurologic findings may include:

• Painful paresthesias
• Numbness
• Weakness
• Reduced reflexes

Severe acute poisoning may initially cause:

• Gastrointestinal symptoms
• Hypotension
• Dysrhythmias
• Encephalopathy

Neuropathy can develop after the acute systemic illness, sometimes with delayed onset.

Chronic exposure may also produce characteristic skin and nail abnormalities.

Thallium

Thallium poisoning classically produces:

• Severe painful peripheral neuropathy
• Paresthesias
• Weakness
• Gastrointestinal symptoms
• Alopecia

A useful diagnostic combination is:

Painful neuropathy + gastrointestinal illness + delayed alopecia → consider thallium

Lead

Chronic lead exposure can produce predominantly motor neuropathy.

Classic findings include:

• Wrist drop
• Foot drop
• Extensor muscle weakness

Other manifestations may include:

• Abdominal pain
• Cognitive or neurologic abnormalities
• Anemia
• Renal abnormalities
• Hypertension

Diagnosis is based primarily on the blood lead concentration and exposure history.

Mercury

Mercury exposure can produce neurologic abnormalities, particularly after chronic exposure.

Possible findings include:

• Tremor
• Paresthesias
• Weakness
• Neuropsychiatric abnormalities

Elemental mercury vapor exposure may additionally produce:

• Gingivostomatitis
• Excessive salivation
• Respiratory injury after substantial inhalation

The clinical pattern varies considerably with the chemical form of mercury.

Isoniazid

Isoniazid can cause peripheral neuropathy by interfering with pyridoxine metabolism.

The neuropathy is typically:

• Symmetric
• Distal
• Sensory or sensorimotor

Risk is increased in patients with nutritional deficiency and other predisposing conditions.

Pyridoxine supplementation is commonly used to prevent neuropathy in patients at increased risk during isoniazid therapy.

n-Hexane

Chronic exposure to n-hexane can cause a progressive sensorimotor axonopathy.

Its neurotoxic metabolite, 2,5-hexanedione, damages peripheral nerves.

Clinical manifestations include:

• Distal paresthesias
• Weakness
• Reduced reflexes
• Progressive motor impairment

Symptoms may continue to worsen temporarily even after exposure stops.

Organophosphates

Most acute organophosphate toxicity produces a cholinergic syndrome, rather than peripheral neuropathy.

However, certain organophosphates can cause organophosphate-induced delayed neuropathy after the acute poisoning.

This may appear after a latent period and cause:

• Distal weakness
• Paresthesias
• Gait abnormalities
• Foot drop
• Progressive motor dysfunction

This delayed neuropathy is mechanistically distinct from the acute cholinergic syndrome.

Vincristine

Vincristine is an important medication-associated cause of peripheral neuropathy.

Possible manifestations include:

• Paresthesias
• Sensory loss
• Weakness
• Reduced reflexes
• Foot drop
• Autonomic dysfunction

Autonomic involvement may contribute to constipation or ileus.

Amiodarone

Chronic amiodarone exposure can occasionally produce peripheral neuropathy.

Associated toxicity may involve other organs, including:

• Thyroid
• Liver
• Lungs
• Eyes

Therefore, neuropathy in a patient receiving long-term amiodarone should be interpreted in the context of other potential medication toxicities.

Colchicine

Colchicine toxicity or chronic colchicine exposure may produce a neuromyopathy rather than an isolated peripheral neuropathy.

Features may include:

• Proximal weakness
• Sensory abnormalities
• Elevated CK
• Reduced reflexes

Risk may increase with renal dysfunction or interacting medications.

Important Nontoxic Causes

Toxic exposure is only one possible cause of peripheral neuropathy.

Common alternatives include:

• Diabetes mellitus
• Vitamin B12 deficiency
• Thiamine deficiency
• Chronic kidney disease/uremia
• Guillain-Barré syndrome
• Nerve compression or trauma
• Hypothyroidism
• Autoimmune disease
• Vasculitis
• Malignancy
• Amyloidosis
• Hereditary neuropathies
• Infections

A toxic cause should therefore not be assumed solely because neuropathy is present.

Guillain-Barré Syndrome

Guillain-Barré syndrome is an important alternative diagnosis, especially when weakness progresses rapidly.

Typical features include:

• Symmetric weakness
• Reduced or absent reflexes
• Progressive ascending involvement
• Possible cranial nerve dysfunction
• Possible respiratory muscle weakness
• Autonomic instability

CSF may demonstrate:

Elevated protein with relatively few cells

However, this finding may be absent early in the disease.

Neuromuscular Disorders That Can Mimic Neuropathy

Several disorders cause weakness without primarily damaging peripheral sensory nerves.

Important examples include:

• Myasthenia gravis
• Lambert-Eaton myasthenic syndrome
• Botulism
• Tick paralysis
• Hypokalemia
• Neuromuscular-blocking drug toxicity
• Myopathy

Careful examination helps determine whether dysfunction is primarily:

Peripheral nerve vs neuromuscular junction vs muscle vs CNS

Clinical Examination

A complete neurologic examination should assess:

Mental Status

Helps identify associated CNS involvement.

Cranial Nerves

Abnormalities may suggest an alternative or specific toxicologic diagnosis.

Motor Function

Assess:

• Strength
• Muscle bulk
• Tone
• Distribution of weakness

Sensory Function

Assess:

• Pain
• Temperature
• Light touch
• Vibration
• Proprioception

Reflexes

Reduced or absent reflexes support peripheral nerve involvement.

Coordination and Gait

Evaluate:

• Ataxia
• Balance
• Proprioceptive dysfunction
• Foot drop

Respiratory Muscle Assessment

Progressive motor neuropathy can involve respiratory muscles.

Warning findings include:

• Dyspnea
• Weak cough
• Difficulty clearing secretions
• Bulbar weakness
• Rapidly progressive generalized weakness

Serial respiratory measurements such as forced vital capacity and inspiratory pressure can help identify impending ventilatory failure.

Pulse oximetry alone may remain normal until relatively late and does not adequately assess ventilation.

Laboratory Evaluation

Testing should be guided by the suspected cause.

Possible investigations include:

• CBC
• Electrolytes
• Glucose
• Renal function
• Liver function
• Vitamin B12
• Thyroid studies
• CK

Targeted toxicologic testing may include:

• Blood lead concentration
• Arsenic testing
• Mercury testing
• Thallium testing

Testing should be based on a credible exposure history and compatible clinical syndrome rather than indiscriminate heavy-metal screening.

Electrodiagnostic Studies

Nerve conduction studies and electromyography (EMG) are useful for characterizing peripheral neuropathy.

They can help determine whether the process is predominantly:

• Axonal
• Demyelinating
• Motor
• Sensory
• Sensorimotor

They can also help distinguish neuropathy from primary muscle or neuromuscular-junction disorders.

Lumbar Puncture

Lumbar puncture is not routinely required for toxic neuropathy.

It may be useful when an alternative neurologic diagnosis is suspected, particularly Guillain-Barré syndrome.

Imaging

MRI may be appropriate when findings suggest:

• Spinal cord disease
• CNS demyelinating disease
• Tumor
• Structural neurologic disease

Imaging is generally used to investigate alternative diagnoses, rather than to confirm toxic peripheral neuropathy.

Nerve Biopsy

Nerve biopsy is rarely required for suspected toxic neuropathy.

It is invasive and generally provides limited additional information when the exposure history, neurologic examination, and electrodiagnostic studies already establish the pattern.

Management

The most important intervention in toxic peripheral neuropathy is:

Identify and discontinue or eliminate the causative exposure.

Management may include:

• Discontinuing the responsible medication when appropriate
• Removing occupational or environmental exposure
• Treating an identified nutritional deficiency
• Treating neuropathic pain
• Physical therapy
• Occupational therapy
• Mobility assistance
• Prevention of falls and injuries

Specific treatment depends on the underlying toxicant.

Decontamination

Gastrointestinal decontamination usually has no role once peripheral neuropathy has developed.

Toxic neuropathies commonly appear after enough time has passed that the original substance has already been absorbed.

The priority is therefore:

Stop ongoing exposure and prevent additional injury.

Antidotes

There is no universal antidote for toxic peripheral neuropathy.

Some underlying poisonings have specific treatments, but these treatments address the toxic exposure rather than directly reversing established nerve damage.

Examples include:

• Chelation for selected confirmed heavy-metal poisonings
• Pyridoxine for appropriate isoniazid-related problems
• Prussian blue for thallium poisoning

Treatment should be directed toward the specific toxicant.

Prognosis

Recovery depends on:

• Toxicant involved
• Severity of nerve injury
• Axonal versus demyelinating injury
• Duration of exposure
• Speed of exposure removal
• Presence of underlying neurologic disease

Neurologic abnormalities may continue to worsen for days or even weeks after exposure stops.

This phenomenon does not necessarily indicate continued exposure.

Axonal regeneration is slow, so recovery may take:

• Weeks
• Months
• Occasionally longer

Some patients recover completely, while others retain residual sensory or motor deficits.

Key Points

• Peripheral neuropathy causes sensory, motor, and/or autonomic dysfunction of peripheral nerves.
• Most toxic neuropathies are symmetric, distal polyneuropathies.
• Axonopathy is a common mechanism of toxic neuropathy.
• Length-dependent axonal injury typically affects the feet before the hands.
• Sensory symptoms include paresthesias, burning pain, numbness, and impaired sensation.
• Motor involvement causes distal weakness, foot drop, wrist drop, muscle wasting, and reduced reflexes.
• Important toxic causes include arsenic, thallium, lead, mercury, isoniazid, nitrous oxide, n-hexane, vincristine, metronidazole, certain organophosphates, and several medications.
• Painful neuropathy followed by alopecia is an important clue to thallium poisoning.
• Wrist or foot drop is classically associated with lead neuropathy.
• Nitrous oxide can produce neurologic dysfunction through functional vitamin B12 inactivation.
• Some organophosphates can produce a delayed neuropathy after the acute cholinergic syndrome has resolved.
• Electrodiagnostic studies help distinguish axonal from demyelinating neuropathy.
• Rapidly progressive weakness requires assessment for respiratory muscle involvement.
• Always consider common nontoxic causes such as diabetes, vitamin deficiencies, uremia, Guillain-Barré syndrome, and nerve compression.
• Treatment centers on removing the causative exposure, treating the specific poisoning when possible, controlling neuropathic symptoms, and rehabilitation.
• Neuropathy may temporarily continue to worsen after exposure stops, and neurologic recovery can require weeks to months.

Toxicology – Osmolal Gap

Definition

The osmolal gap is the difference between the measured serum osmolality and the calculated serum osmolality.

It is primarily used in toxicology as a screening clue for the presence of unmeasured, osmotically active substances, particularly toxic alcohols.

The terms:

• Osmolal gap
• Osmolar gap
• Osmol gap

are often used interchangeably clinically, although osmolal gap is technically the preferred term when serum osmolality is measured.

⸻

Calculation

A commonly used calculated serum osmolality equation is:

Calculated serum osmolality ≈ 2 × Na + glucose/18 + BUN/2.8

when glucose and BUN are reported in mg/dL.

If ethanol is known to be present, some clinical formulas incorporate its osmotic contribution when interpreting the residual gap.

⸻

Normal Osmolal Gap

A value around −10 to +10 mOsm/kg is commonly considered within the expected range, although the reference interval depends on:

• Laboratory method
• Calculation formula
• Individual baseline
• Whether ethanol is included in the calculation

Therefore, a rigid cutoff should not be used to exclude poisoning.

⸻

Clinical Significance

An elevated osmolal gap indicates the presence of unmeasured osmotically active substances.

Important toxicologic causes include:

• Methanol
• Ethylene glycol
• Isopropanol
• Ethanol
• Propylene glycol
• Acetone

Other causes include:

• Mannitol
• Ketoacidosis
• Renal failure
• Shock or critical illness
• Some other endogenous or administered osmoles

An elevated gap is therefore not specific for toxic alcohol poisoning.

⸻

Pathophysiology

Measured serum osmolality reflects the total concentration of dissolved osmotically active particles in serum.

Routine calculation estimates the major measured contributors:

• Sodium and accompanying anions
• Glucose
• Urea

If another osmotically active substance is present but is not included in the calculation:

Measured osmolality rises → calculated osmolality does not rise proportionally → osmolal gap increases

This is the principle behind using the gap to detect toxic alcohols.

⸻

Measurement of Serum Osmolality

Serum osmolality should preferably be measured using freezing-point depression.

This method is appropriate for detecting the osmotic effects of volatile alcohols.

Older vapor-pressure techniques may fail to accurately account for volatile substances and are unsuitable when toxic alcohol exposure is suspected.

⸻

Important Toxicologic Causes

Methanol

Methanol itself increases the osmolal gap.

It is metabolized to:

• Formaldehyde
• Formic acid/formate

The metabolites are responsible for much of the severe toxicity.

Clinical manifestations include:

• CNS depression
• Nausea/vomiting
• Abdominal discomfort
• Tachypnea
• High-anion-gap metabolic acidosis
• Visual disturbances

Severe poisoning may cause:

• Blindness
• Seizures
• Coma
• Cardiovascular collapse

⸻

Methanol and Visual Toxicity

Visual manifestations are particularly suggestive of methanol poisoning.

Patients may report:

• Blurred vision
• Reduced visual acuity
• Photophobia
• Visual field abnormalities
• A “snowfield” or “snowstorm” appearance

Severe toxicity can produce optic nerve injury and permanent blindness.

⸻

Ethylene Glycol

Ethylene glycol initially behaves as an osmotically active alcohol and therefore may increase the osmolal gap.

It is subsequently metabolized to toxic acids.

Clinical manifestations may include:

• CNS depression
• Nausea/vomiting
• High-anion-gap metabolic acidosis
• Hypocalcemia
• Acute kidney injury

Calcium oxalate crystalluria may occur but is neither sufficiently sensitive nor specific to exclude or confirm poisoning by itself.

⸻

Isopropanol

Isopropanol is metabolized to acetone.

Clinical manifestations include:

• CNS depression
• Dizziness
• Nausea/vomiting
• Abdominal pain
• Hypotension in severe cases
• Hemorrhagic gastritis

A classic laboratory pattern is:

Elevated osmolal gap + ketosis without significant high-anion-gap metabolic acidosis

This occurs because acetone is a ketone but not a strong organic acid.

⸻

Ethanol

Ethanol is a common cause of an elevated osmolal gap.

It may produce:

• Disinhibition
• Ataxia
• Dysarthria
• CNS depression
• Hypoglycemia, particularly in young children
• Respiratory depression in severe intoxication

When interpreting an osmolal gap for suspected toxic alcohol poisoning, the contribution from ethanol should be considered.

⸻

Propylene Glycol

Propylene glycol is used as a solvent in some medications.

Large or prolonged exposures can cause:

• Elevated osmolal gap
• Lactic acidosis
• CNS depression
• Renal dysfunction

Risk is increased when substantial quantities of propylene-glycol-containing medications are administered, particularly in critically ill patients.

⸻

Osmolal Gap and Anion Gap

The osmolal gap and anion gap provide different information.

The anion gap is commonly calculated as:

Laboratory reference ranges vary depending on measurement methods and whether potassium is included.

⸻

Relationship During Toxic Alcohol Poisoning

Understanding the time course is extremely important.

Early Poisoning

Soon after ingestion, much of the toxic alcohol remains as the parent compound.

Therefore:

Parent alcohol ↑ → osmolal gap ↑

The anion gap may still be normal because relatively little toxic acid metabolite has formed.

⸻

Later Poisoning

As methanol or ethylene glycol is metabolized:

Parent alcohol ↓ → osmolal gap ↓

At the same time:

Toxic organic acids ↑ → anion gap metabolic acidosis ↑

Therefore, the typical progression is:

Early → high osmolal gap, little acidosis

Later → falling osmolal gap, increasing anion-gap acidosis

⸻

Major Diagnostic Pitfall

A normal osmolal gap does NOT exclude methanol or ethylene glycol poisoning.

This is one of the most important concepts.

A patient presenting late may have already metabolized much of the parent alcohol.

Therefore:

Normal osmolal gap + severe high-anion-gap metabolic acidosis can still represent advanced toxic alcohol poisoning.

Clinical suspicion should not be dismissed simply because the osmolal gap has normalized.

⸻

Anion Gap Can Also Be Normal Early

Likewise, a normal anion gap does not exclude an early toxic alcohol exposure.

Before sufficient toxic metabolites accumulate:

• Osmolal gap may already be elevated.
• Anion gap may remain normal.

Thus neither gap should be interpreted independently.

⸻

Clinical Features

The osmolal gap itself causes no symptoms.

Symptoms arise from the substance responsible for the gap.

Possible manifestations include:

• Intoxication
• CNS depression
• Ataxia
• Nausea/vomiting
• Abdominal pain
• Tachypnea
• Hypotension
• Seizures
• Coma

Specific findings can help identify the responsible toxicant.

⸻

Diagnostic Evaluation

When toxic alcohol poisoning is suspected, evaluation may include:

• Measured serum osmolality
• Sodium
• Glucose
• BUN
• Electrolytes
• Bicarbonate
• Anion gap
• Blood gas
• Lactate
• Renal function
• Glucose
• ECG

When available, obtain specific concentrations of:

• Methanol
• Ethylene glycol
• Ethanol
• Isopropanol

Direct measurement of the suspected alcohol is preferable to relying solely on calculated gaps.

⸻

Additional Findings in Ethylene Glycol Poisoning

Consider:

• Hypocalcemia
• Acute kidney injury
• Calcium oxalate crystalluria
• Metabolic acidosis

Renal injury may become prominent later in the course.

⸻

Additional Findings in Methanol Poisoning

Consider:

• Severe metabolic acidosis
• Elevated anion gap
• Visual symptoms
• Optic nerve injury
• CNS deterioration

The combination of:

Unexplained high-anion-gap metabolic acidosis + visual symptoms

should raise strong concern for methanol toxicity.

⸻

Treatment Principles

Treatment depends on the underlying toxicant rather than the osmolal gap itself.

Initial management includes:

• Stabilize airway, breathing, and circulation.
• Correct major metabolic abnormalities.
• Obtain appropriate laboratory studies.
• Identify the suspected exposure.
• Consult a poison center or medical toxicologist when significant toxic alcohol poisoning is suspected.

⸻

Fomepizole

Fomepizole is the preferred antidote for methanol and ethylene glycol poisoning.

It inhibits alcohol dehydrogenase, preventing formation of the toxic metabolites responsible for major organ injury.

Treatment should not necessarily be delayed while awaiting confirmatory concentrations when the exposure history and clinical findings strongly suggest significant methanol or ethylene glycol poisoning.

⸻

Ethanol as an Alternative Antidote

Ethanol also competitively inhibits alcohol dehydrogenase and historically has been used to treat methanol and ethylene glycol poisoning.

However, it is more difficult to use safely because it can cause:

• CNS depression
• Hypoglycemia
• Hypotension
• Variable serum concentrations
• Complex monitoring requirements

Therefore:

Fomepizole is generally preferred.

Ethanol is primarily an alternative when fomepizole is unavailable and should be managed under specialist guidance.

⸻

Hemodialysis

Hemodialysis can rapidly remove:

• Methanol
• Ethylene glycol
• Their toxic metabolites

It also helps correct:

• Severe metabolic acidosis
• Electrolyte abnormalities

Dialysis is particularly important in selected severe poisonings involving features such as:

• Severe metabolic acidosis
• Significant end-organ toxicity
• Visual toxicity from methanol
• Significant renal dysfunction with ethylene glycol
• Severe clinical deterioration
• High toxic alcohol burden

Modern decisions should integrate the clinical condition, acid-base status, renal function, and measured toxic alcohol concentration, rather than relying on a single rigid threshold.

⸻

Isopropanol Treatment

Most isopropanol poisoning is treated with supportive care.

Management may include:

• Airway support
• IV fluids
• Treatment of hypotension
• Management of gastrointestinal irritation

Unlike methanol and ethylene glycol poisoning:

Fomepizole is generally NOT indicated for isolated isopropanol poisoning.

Blocking alcohol dehydrogenase would delay conversion of isopropanol to its less toxic metabolite, acetone.

Hemodialysis is reserved for unusual, exceptionally severe cases.

⸻

Gastrointestinal Decontamination

Activated charcoal is generally not useful for isolated toxic alcohol ingestion because these small alcohol molecules are poorly adsorbed and rapidly absorbed.

Induced vomiting is not recommended.

Routine gastric lavage is also not recommended.

Management should instead focus on:

• Early recognition
• Antidotal therapy when appropriate
• Correction of metabolic abnormalities
• Hemodialysis when indicated

⸻

Monitoring

Significant suspected toxic alcohol poisoning requires serial assessment of:

• Mental status
• Vital signs
• Acid-base status
• Anion gap
• Electrolytes
• Renal function
• Osmolal gap

Specific toxic alcohol concentrations should be followed when available.

A falling osmolal gap should not automatically be interpreted as clinical improvement.

⸻

Expected Course

Methanol and Ethylene Glycol

The parent alcohol initially causes intoxication and an increased osmolal gap.

As metabolism progresses:

• Parent alcohol concentration decreases.
• Osmolal gap falls.
• Toxic metabolites accumulate.
• Metabolic acidosis and organ injury increase.

Early recognition and inhibition of alcohol dehydrogenase substantially reduce toxicity.

Isopropanol

Usually causes relatively rapid intoxication and ketosis.

Most patients recover with supportive care, although severe exposures can cause:

• Profound CNS depression
• Hypotension
• Hemorrhagic gastritis

⸻

Key Points

• The osmolal gap = measured serum osmolality − calculated serum osmolality.
• It is a screening clue for unmeasured osmotically active substances.
• Important toxicologic causes include methanol, ethylene glycol, isopropanol, ethanol, propylene glycol, and acetone.
• An elevated osmolal gap is not specific for toxic alcohol poisoning.
• A normal osmolal gap does not exclude methanol or ethylene glycol poisoning.
• Early methanol/ethylene glycol poisoning may produce a high osmolal gap with little or no anion-gap acidosis.
• As toxic alcohol metabolism progresses, the osmolal gap falls while the anion gap rises.
• Methanol classically causes visual toxicity and severe metabolic acidosis.
• Ethylene glycol can cause metabolic acidosis, hypocalcemia, calcium oxalate crystalluria, and acute kidney injury.
• Isopropanol classically produces ketosis without significant high-anion-gap metabolic acidosis.
• Direct toxic alcohol concentrations are preferable when available.
• Fomepizole is the preferred antidote for methanol and ethylene glycol poisoning.
• Fomepizole is generally not indicated for isolated isopropanol poisoning.
• Hemodialysis is an important treatment for selected severe methanol and ethylene glycol poisonings.
• Activated charcoal is generally ineffective for isolated toxic alcohol ingestion.
• Never interpret the osmolal gap alone; combine it with the exposure history, clinical findings, anion gap, acid-base status, and specific toxicant concentrations when available.

Toxicology – High-Risk Low-Dose Pediatric Poisoning

Definition

High-risk low-dose pediatric poisoning refers to accidental exposure to medications or chemicals capable of producing severe or potentially fatal toxicity after ingestion of a relatively small amount by a young child.

Young children are particularly susceptible because their low body weight means that even a single adult-strength tablet or small volume of a concentrated product may represent a substantial weight-adjusted toxic exposure.

Although most accidental childhood ingestions cause minimal toxicity, certain substances have:

• A narrow therapeutic index
• High intrinsic toxicity
• Potent cardiovascular or neurologic effects
• Delayed toxicity
• Long duration of action

These exposures require careful assessment even when the child is initially asymptomatic.

Major High-Risk Drug Classes

Sulfonylureas

Sulfonylureas are important causes of severe pediatric hypoglycemia.

Examples include:

• Glyburide/glibenclamide
• Glipizide
• Glimepiride
• Gliclazide

A relatively small exposure may stimulate excessive pancreatic insulin release.

Clinical manifestations include:

• Sweating
• Pallor
• Irritability
• Lethargy
• Confusion
• Seizures
• Coma

Hypoglycemia may be delayed, prolonged, or recurrent.

Treatment includes correction of hypoglycemia, with octreotide used in clinically significant sulfonylurea poisoning to suppress further insulin secretion.

Opioids

Young children are highly susceptible to opioid-induced respiratory depression.

Important agents include:

• Methadone
• Codeine
• Hydrocodone
• Other potent or long-acting opioids

Typical findings include:

• CNS depression
• Miosis
• Bradypnea
• Hypoventilation
• Bradycardia
• Hypotension

The most dangerous manifestation is respiratory failure.

Naloxone is indicated when clinically significant opioid-induced respiratory depression is present.

The therapeutic goal is restoration of adequate ventilation rather than complete awakening.

Clonidine and Imidazoline Agents

Clonidine and related imidazolines may cause substantial toxicity following a small pediatric exposure.

Clinical findings include:

• Somnolence
• Miosis
• Bradycardia
• Hypotension
• Respiratory depression

The syndrome may closely resemble opioid toxicity.

An early transient hypertensive phase can occasionally occur.

Tricyclic Antidepressants

Tricyclic antidepressants can produce rapidly progressive neurologic and cardiovascular toxicity.

Examples include:

• Amitriptyline
• Imipramine
• Desipramine

Clinical manifestations include:

• Anticholinergic findings
• Altered mental status
• Seizures
• Hypotension
• QRS widening
• Ventricular dysrhythmias

Severe cardiotoxicity primarily results from fast sodium-channel blockade.

Significant sodium-channel cardiotoxicity is treated with sodium bicarbonate.

Calcium Channel Blockers

Calcium channel blockers can cause severe cardiovascular poisoning.

Important agents include:

• Verapamil
• Diltiazem
• Nifedipine

Manifestations include:

• Bradycardia
• AV conduction abnormalities
• Myocardial depression
• Peripheral vasodilation
• Hypotension
• Cardiogenic or mixed shock

Hyperglycemia is an important clue to significant calcium channel blocker toxicity.

Extended-release preparations may produce delayed and prolonged toxicity.

Severe poisoning may require:

• Calcium
• Vasopressors
• Hyperinsulinemic euglycemia therapy
• Advanced circulatory support

Beta-Adrenergic Blockers

Beta-blocker poisoning may produce:

• Bradycardia
• Hypotension
• AV block
• Reduced myocardial contractility
• CNS depression

Some beta-blockers may additionally cause:

• Seizures
• QRS widening
• Ventricular dysrhythmias

Hypoglycemia can occur, particularly in young children.

Severe cases may require vasopressors and hyperinsulinemic euglycemia therapy, with other therapies selected according to the specific beta-blocker and clinical syndrome.

Antimalarial Agents

Certain antimalarial medications can cause profound cardiovascular toxicity following relatively small pediatric exposures.

Important examples include:

• Chloroquine
• Hydroxychloroquine
• Quinine

Severe toxicity may cause:

• Hypotension
• QRS widening
• QT abnormalities
• Ventricular dysrhythmias
• Seizures
• Hypokalemia
• Cardiovascular collapse

These exposures require urgent medical assessment.

Theophylline

Theophylline has a narrow therapeutic index.

Toxicity may produce:

• Nausea and vomiting
• Tremor
• Agitation
• Tachycardia
• Hypokalemia
• Hyperglycemia
• Seizures
• Ventricular dysrhythmias

Extended-release preparations can cause delayed and prolonged toxicity.

Diphenoxylate

Diphenoxylate-containing antidiarrheal medications can produce opioid-like toxicity in children.

Manifestations include:

• CNS depression
• Miosis
• Respiratory depression
• Bradycardia

Toxicity may be delayed or prolonged.

Naloxone may reverse clinically significant opioid effects.

High-Risk Small-Volume Chemical Exposures

Methanol

Methanol is metabolized to toxic metabolites that can produce:

• High-anion-gap metabolic acidosis
• Visual impairment
• CNS depression
• Seizures
• Coma

Severe poisoning can cause permanent visual and neurologic injury.

Fomepizole inhibits toxic metabolite formation.

Severe poisoning may require hemodialysis.

Ethylene Glycol

Ethylene glycol metabolism produces toxic organic acids.

Clinical manifestations may include:

• CNS depression
• High-anion-gap metabolic acidosis
• Hypocalcemia
• Acute kidney injury

Treatment includes fomepizole, supportive care, and hemodialysis in severe cases.

Methyl Salicylate

Methyl salicylate, commonly found in oil of wintergreen, is a highly concentrated salicylate preparation.

Significant poisoning can produce:

• Vomiting
• Tachypnea
• Diaphoresis
• Tinnitus
• Respiratory alkalosis
• High-anion-gap metabolic acidosis
• Hyperthermia
• Altered mental status

Serial salicylate concentrations and acid-base assessment are important.

Severe toxicity may require urinary alkalinization and hemodialysis.

Camphor

Camphor can produce rapid CNS toxicity.

Manifestations include:

• Nausea
• Vomiting
• Agitation
• Confusion
• Seizures

Neurologic deterioration may occur rapidly after exposure.

Hydrofluoric Acid and Fluoride Compounds

Concentrated fluoride exposure can produce both local tissue injury and severe systemic electrolyte abnormalities.

Potential complications include:

• Hypocalcemia
• Hypomagnesemia
• Hyperkalemia
• QT prolongation
• Ventricular dysrhythmias
• Cardiovascular collapse

These exposures require urgent assessment and correction of electrolyte abnormalities.

Corrosive Substances

Concentrated acids and alkalis may cause severe injury even after relatively small exposures.

Potential complications include:

• Oropharyngeal injury
• Airway edema
• Esophageal burns
• Gastric injury
• Perforation
• Later stricture formation

The absence of oral burns does not exclude significant esophageal injury.

Do not induce vomiting or attempt chemical neutralization.

Activated charcoal generally has no role in corrosive ingestion.

Organophosphate Insecticides

Concentrated organophosphate exposure causes excessive acetylcholine accumulation.

Muscarinic manifestations include:

• Miosis
• Salivation
• Lacrimation
• Bronchorrhea
• Bronchospasm
• Vomiting
• Diarrhea
• Bradycardia

Nicotinic manifestations include:

• Fasciculations
• Weakness
• Paralysis

Severe poisoning can cause respiratory failure.

Treatment includes atropine, supportive respiratory care, and pralidoxime for significant organophosphate poisoning.

Paraquat

Paraquat poisoning can cause severe multisystem toxicity.

Early manifestations may include:

• Oral and gastrointestinal corrosive injury
• Nausea
• Vomiting
• Abdominal pain

Severe poisoning may progress to:

• Acute kidney injury
• Hepatic injury
• Progressive pulmonary toxicity
• Multiorgan failure

Suspected ingestion requires immediate specialist toxicology assessment.

Concentrated Hydrogen Peroxide

Highly concentrated hydrogen peroxide can release large quantities of oxygen after contact with tissues.

Potential complications include:

• Gastrointestinal irritation
• Gastric distension
• Mucosal injury
• Gas embolism
• Neurologic complications
• Cardiovascular instability

Toxicity depends strongly on the concentration and amount of product involved.

Amatoxin-Containing Mushrooms

Certain mushrooms, particularly Amanita phalloides and related amatoxin-containing species, can cause severe hepatic toxicity.

Typical progression:

Latent asymptomatic phase → severe gastroenteritis → temporary clinical improvement → hepatic failure

The apparent improvement after gastrointestinal symptoms can be misleading.

Severe cases may progress to:

• Coagulopathy
• Hypoglycemia
• Encephalopathy
• Multiorgan failure

Lead-Containing Foreign Bodies

Ingested lead-containing objects can cause significant toxicity when retained within the gastrointestinal tract.

Potential consequences include:

• Elevated blood lead concentrations
• Abdominal symptoms
• Neurologic toxicity
• Hematologic abnormalities

Management depends on the location and retention of the object, blood lead concentration, and clinical condition.

Major Toxicologic Syndromes

Respiratory Depression

Important causes:

• Opioids
• Clonidine/imidazolines
• Diphenoxylate

Clinical priority:

Assess ventilation and airway protection.

Hypoglycemia

Important cause:

• Sulfonylureas

Because hypoglycemia may recur, serial glucose monitoring is essential.

Cardiovascular Toxicity

Important causes:

• Tricyclic antidepressants
• Calcium channel blockers
• Beta-blockers
• Chloroquine/hydroxychloroquine

Possible manifestations:

• Bradycardia
• Conduction abnormalities
• QRS widening
• Dysrhythmias
• Hypotension
• Shock

Seizures

Important toxicologic causes include:

• Tricyclic antidepressants
• Theophylline
• Camphor
• Chloroquine
• Stimulants

Seizures may contribute to:

• Hyperthermia
• Lactic acidosis
• Rhabdomyolysis
• Hypoxia

Delayed Organ Toxicity

Important causes include:

• Methanol
• Ethylene glycol
• Amatoxin-containing mushrooms
• Paraquat
• Extended-release medications

Therefore, the absence of early symptoms does not necessarily indicate a benign exposure.

Evaluation of the Initially Asymptomatic Child

A normal initial examination does not reliably exclude serious poisoning.

Delayed toxicity can result from:

• Extended-release formulations
• Delayed gastrointestinal absorption
• Formation of toxic metabolites
• Long drug half-lives
• Recurrent hypoglycemia
• Delayed hepatic, renal, or pulmonary injury

Observation should therefore be determined by the specific toxicant and formulation, rather than using a universal observation period.

Exposure History

Important information includes:

• Exact medication or chemical
• Active ingredient
• Formulation
• Concentration or tablet strength
• Immediate-release versus extended-release preparation
• Child’s weight
• Maximum possible amount involved
• Time of exposure
• Presence of coingestants
• Current symptoms

Whenever possible, the original medication or product container should be identified.

Initial Clinical Assessment

Evaluate:

• Airway patency
• Respiratory rate and effort
• Ventilation
• Oxygenation
• Mental status
• Heart rate
• Blood pressure
• Temperature
• Pupils
• Neuromuscular findings

A bedside blood glucose should be obtained early in unexplained altered mental status, seizures, or suspected hypoglycemic-agent exposure.

ECG Assessment

ECG monitoring is particularly important with suspected:

• Tricyclic antidepressants
• Sodium-channel blockers
• Beta-blockers
• Calcium channel blockers
• Chloroquine/hydroxychloroquine
• Other cardiotoxic medications

Important abnormalities include:

• Bradycardia
• AV block
• QRS widening
• QT prolongation
• Ventricular dysrhythmias

Laboratory Evaluation

Testing should be directed by the suspected exposure.

Possible studies include:

• Glucose
• Electrolytes
• Renal function
• Blood gas
• Lactate
• Acetaminophen concentration when indicated
• Salicylate concentration
• Toxic alcohol evaluation
• Drug-specific concentrations when clinically useful

Routine broad toxicology screening should not replace a careful exposure history and targeted testing.

Management Principles

The general approach is:

Identify exposure → assess ABCs → recognize expected toxidrome → anticipate delayed toxicity → initiate specific/supportive treatment → monitor appropriately

Potentially dangerous pediatric ingestions can deteriorate rapidly despite an initially normal examination.

Gastrointestinal Decontamination

Induced vomiting is not recommended.

Routine gastric lavage is generally not indicated.

Activated charcoal may be considered for selected potentially serious recent ingestions when:

• The substance is effectively adsorbed,
• A meaningful clinical benefit is expected, and
• The airway is adequately protected.

Decontamination should never delay stabilization or administration of an urgently required antidote.

Observation and Disposition

Observation duration should be toxicant-specific.

Prolonged monitoring may be required for:

• Extended-release medications
• Sulfonylureas
• Long-acting opioids
• Calcium channel blockers
• Toxic alcohols
• Substances causing delayed organ injury

Symptomatic patients or children with potentially serious exposures generally require monitored medical evaluation.

Key Points

• High-risk low-dose pediatric poisoning is a more clinically descriptive term for the traditional “one pill can kill” concept.
• It describes medications or chemicals capable of producing severe toxicity from relatively small pediatric exposures.
• Young children are particularly vulnerable because a small absolute amount may represent a large weight-adjusted dose.
• Important high-risk medications include sulfonylureas, opioids, clonidine, TCAs, calcium channel blockers, beta-blockers, antimalarials, and theophylline.
• Sulfonylureas can cause delayed and recurrent hypoglycemia.
• Opioids and clonidine can cause CNS and respiratory depression.
• TCAs and other cardiotoxic medications can cause seizures, conduction abnormalities, dysrhythmias, and shock.
• Small-volume chemical exposures can also be dangerous, particularly toxic alcohols, concentrated salicylates, corrosives, hydrofluoric acid, paraquat, and concentrated hydrogen peroxide.
• Some dangerous poisonings have an initially asymptomatic period.
• Obtain the exact product, formulation, strength, timing, maximum possible exposure, and child’s weight.
• Observation and treatment should be based on the specific toxicant and its pharmacokinetics, rather than a universal “one-pill” rule.

Here’s the paraphrased study-note version:

175. Toxicology – Odors as Diagnostic Clues

Definition

Certain toxic substances have characteristic odors that may provide a diagnostic clue during poisoning.

However, odor should never be used alone to identify a poison because:

• Odor perception varies greatly between individuals.
• Some people cannot detect particular odors.
• Several chemicals can produce similar smells.
• Multiple odors may mask one another.
• Olfactory fatigue can cause an odor to disappear even while the toxicant remains present.

Therefore:

Characteristic odor + exposure history + toxidrome + appropriate testing is much more useful than odor alone.

Olfactory Physiology

Most odors are detected by receptors located high within the nasal cavity.

Signals travel through:

Olfactory receptors → cranial nerve I → olfactory bulb → olfactory cortex/CNS

Some irritating chemicals also strongly stimulate the trigeminal nerve (cranial nerve V).

Examples include:

• Ammonia
• Other irritating vapors

This trigeminal stimulation contributes to sensations such as:

• Burning
• Stinging
• Irritation

Olfactory Fatigue

Olfactory fatigue is rapid adaptation to a persistent odor.

After continued exposure:

Odor initially detected → olfactory adaptation → odor becomes difficult or impossible to perceive

This is particularly dangerous with hydrogen sulfide.

A person may initially smell its characteristic rotten-egg odor and then stop noticing it despite continued exposure.

Therefore:

Loss of odor does NOT mean the environment is safe.

Important Odor Associations

Bitter Almond Odor

Classically associated with:

• Cyanide

However, the bitter-almond odor is an unreliable diagnostic sign because many people are genetically unable to detect it.

Cyanide should instead be suspected from:

• Compatible exposure
• Rapid neurologic deterioration
• Cardiovascular collapse
• Severe lactic acidosis

Rotten-Egg Odor

Important associations include:

• Hydrogen sulfide
• Sulfur-containing compounds
• Mercaptans

Hydrogen sulfide poisoning can cause:

• Eye and airway irritation
• Headache
• Dizziness
• Rapid CNS depression
• Seizures
• Respiratory failure
• Cardiovascular collapse

Hydrogen sulfide causes rapid olfactory fatigue, making smell especially unreliable as a safety warning.

Natural Gas Odor

Natural gas itself is normally given a warning odor by adding odorants such as mercaptans.

Therefore, the characteristic sulfur-like smell associated with household natural gas primarily reflects the added odorant rather than the fuel gas itself.

Garlic-Like Odor

Possible toxicologic associations include:

• Organophosphate pesticides
• Arsenic compounds
• Selenium
• Phosphorus
• Phosphine
• Tellurium

A garlic-like odor is not sufficiently specific to diagnose any of these exposures.

Associated clinical findings are much more useful.

Garlic Odor + Cholinergic Findings

Consider organophosphate poisoning when an exposure is accompanied by:

• Miosis
• Salivation
• Lacrimation
• Sweating
• Bronchorrhea
• Bronchospasm
• Vomiting
• Diarrhea
• Fasciculations
• Weakness

The cholinergic toxidrome is much more diagnostically important than odor.

Garlic or Fish-Like Odor + Severe Illness

Metal phosphides can release phosphine gas.

Potential exposures include:

• Aluminum phosphide
• Zinc phosphide
• Other metal phosphides

Severe poisoning can produce:

• Vomiting
• Abdominal pain
• Hypotension
• Metabolic acidosis
• Myocardial dysfunction
• Dysrhythmias
• Respiratory failure

A characteristic odor may occur but should not be relied upon for diagnosis.

Freshly Cut Hay or Musty Odor

Classically associated with:

• Phosgene

Phosgene exposure can initially cause relatively mild symptoms followed by delayed pulmonary injury.

Possible findings include:

• Cough
• Chest tightness
• Dyspnea
• Hypoxemia
• Pulmonary edema

A potentially dangerous feature is the delay between exposure and severe respiratory deterioration.

Chlorine/Bleach-Like Odor

Consider:

• Chlorine
• Other irritating halogen gases

Clinical effects may include:

• Eye irritation
• Burning throat
• Cough
• Chest tightness
• Bronchospasm
• Dyspnea

Severe exposure may cause acute lung injury and pulmonary edema.

Ammonia-Like Odor

Ammonia is a highly water-soluble respiratory irritant.

Exposure may produce:

• Eye pain
• Lacrimation
• Nasal and throat burning
• Cough
• Bronchospasm
• Upper-airway injury

High concentrations can produce severe airway and pulmonary injury.

An ammonia-like odor can also occur with uremia, although this is not a toxicant exposure.

Fruity or Acetone-Like Odor

Possible causes include:

• Acetone
• Isopropyl alcohol exposure
• Diabetic ketoacidosis
• Alcoholic ketoacidosis
• Some volatile solvents

Isopropyl alcohol is metabolized to acetone.

Typical isopropanol toxicity includes:

• CNS depression
• Nausea/vomiting
• Abdominal pain
• Hypotension in severe cases
• Ketosis

A major clue is:

Ketosis without the prominent high-anion-gap metabolic acidosis expected from ketoacidosis

Wintergreen Odor

A wintergreen or mint-like odor suggests:

• Methyl salicylate (oil of wintergreen)

Methyl salicylate poisoning produces the same systemic toxicity as other salicylates.

Possible findings include:

• Tachypnea
• Tinnitus
• Nausea/vomiting
• Diaphoresis
• Acid-base disturbances
• Altered mental status in severe poisoning

A serum salicylate concentration should be measured when clinically suspected.

Mothball Odor

Possible exposures include:

• Naphthalene
• Paradichlorobenzene
• Camphor-containing products

The clinical syndrome depends on the substance involved.

Naphthalene

Can cause:

• Oxidative hemolysis
• Methemoglobinemia
• Abdominal symptoms

Patients with G6PD deficiency are particularly susceptible to oxidative hemolysis.

Camphor

Significant ingestion may produce:

• Nausea/vomiting
• Agitation
• Seizures
• CNS toxicity

Therefore, identifying the actual moth-repellent ingredient is more important than recognizing the odor.

Paint or Solvent Odor

May suggest:

• Toluene
• Other volatile hydrocarbons/solvents

Toluene toxicity may cause:

• Euphoria followed by CNS depression
• Ataxia
• Confusion
• Weakness
• Hypokalemia
• Acid-base abnormalities

Chronic exposure may cause neurologic and renal abnormalities.

A paint odor on clothing or skin may support the exposure history but is not diagnostic.

Shoe-Polish-Like Odor

Historically associated with:

• Nitrobenzene
• Aniline compounds

These oxidizing chemicals can produce methemoglobinemia.

Clinical clues include:

• Cyanosis
• Dyspnea
• Headache
• Altered mental status
• Chocolate-brown blood
• Pulse oximetry that does not normalize appropriately with oxygen

Diagnosis requires co-oximetry.

Vinegar Odor

May suggest:

• Acetic acid

Concentrated acetic acid can cause corrosive injury.

Possible findings include:

• Oral or airway irritation
• Chest or abdominal pain
• Vomiting
• GI injury

Management should be based on the degree of corrosive exposure rather than the odor itself.

Tobacco Odor

May support exposure to:

• Nicotine-containing products

Significant nicotine toxicity can initially cause cholinergic-type stimulation with:

• Nausea
• Vomiting
• Abdominal pain
• Salivation
• Tachycardia
• Hypertension
• Tremor

Severe poisoning may progress to:

• Bradycardia
• Hypotension
• Weakness
• Seizures
• Respiratory failure

Odor + Clinical Findings

Odors become more useful when interpreted together with a toxidrome.

Examples:

Garlic odor + miosis + bronchorrhea + fasciculations

→ consider organophosphate poisoning

Rotten-egg odor + rapid CNS/cardiovascular collapse

→ consider hydrogen sulfide

Wintergreen odor + tachypnea + tinnitus + acid-base disturbance

→ consider methyl salicylate

Mothball odor + hemolysis/methemoglobinemia

→ consider naphthalene

Paint odor + CNS depression + hypokalemia

→ consider toluene

Fruity odor + CNS depression + ketosis

→ consider isopropanol/acetone

Bitter-almond odor + profound lactic acidosis/collapse

→ consider cyanide, while remembering that odor detection is unreliable

Laboratory Evaluation

Testing should be directed by the suspected toxicant and clinical presentation.

Possible investigations include:

• Electrolytes
• Glucose
• Bicarbonate
• BUN and creatinine
• Blood gas
• Lactate
• Serum osmolality
• Ketones
• ECG

Targeted testing may include:

• Salicylate concentration
• Co-oximetry
• Carboxyhemoglobin
• Methemoglobin
• Specific toxicant concentrations when clinically available

Lactate

Marked lactate elevation may occur with:

• Cyanide
• Hydrogen sulfide
• Carbon monoxide
• Severe hypoxia
• Shock
• Seizures

Lactate is therefore useful for assessing severity but is not specific for one poison.

Acid-Base Findings

A high-anion-gap metabolic acidosis may occur with several toxic exposures and other illnesses.

Examples include:

• Salicylate toxicity
• Cyanide
• Severe carbon monoxide poisoning
• Hydrogen sulfide poisoning
• Shock
• Seizures
• Diabetic ketoacidosis

Toluene can produce hypokalemia with a normal-anion-gap metabolic acidosis, although acid-base findings vary depending on timing and exposure.

Chest Imaging

Chest radiography may be appropriate after significant inhalational exposure when there is:

• Dyspnea
• Hypoxemia
• Abnormal lung examination
• Persistent respiratory symptoms

Pulmonary infiltrates or edema may develop after severe exposure to:

• Chlorine
• Ammonia
• Phosgene
• Phosphine
• Other severe inhalational irritants

Some pulmonary injuries can be delayed, so an initially normal chest radiograph does not always exclude significant exposure.

Management

Management is based on the suspected toxicant and clinical syndrome, not the odor itself.

General priorities include:

• Remove the patient from ongoing exposure.
• Protect rescuers and healthcare personnel from secondary exposure.
• Stabilize airway, breathing, and circulation.
• Provide oxygen when indicated.
• Treat seizures and dysrhythmias.
• Correct important electrolyte and acid-base abnormalities.
• Use a specific antidote when indicated for the identified or strongly suspected poison.

Decontamination

Inhalational Exposure

Remove the patient from the contaminated environment.

Rescuers should not enter a hazardous atmosphere without appropriate protective equipment.

Dermal Exposure

When clinically appropriate:

• Remove contaminated clothing.
• Irrigate exposed skin thoroughly.

Ingestion

Gastrointestinal decontamination depends on:

• Specific toxicant
• Timing
• Amount
• Clinical condition
• Airway status

Do not induce vomiting.

Routine gastric lavage is not recommended.

Important Diagnostic Pitfalls

No Odor Does Not Exclude Poisoning

A dangerous toxicant may:

• Have little or no odor
• Be present below the person’s odor threshold
• Be masked by another smell
• Be undetectable because the person has impaired olfaction

Therefore, absence of smell provides no reliable reassurance.

Odor Disappearance Does Not Mean Safety

This is particularly important with hydrogen sulfide.

Olfactory fatigue → smell disappears while toxic exposure continues

Never use the ability to smell a gas as a measure of environmental safety.

Odor Is Not Proof of Toxicity

Some substances can be smelled at concentrations far below those producing toxicity.

Conversely, some dangerous exposures can occur without a noticeable odor.

Key Points

• Characteristic odors can provide a supporting diagnostic clue, but they rarely identify a poison reliably by themselves.
• Most odor perception occurs through cranial nerve I, while irritating vapors can also stimulate cranial nerve V.
• Olfactory fatigue can make an odor disappear despite continued exposure.
• Hydrogen sulfide is the classic example where relying on smell can be especially dangerous.
• Bitter almond → cyanide, but many people cannot detect this odor.
• Rotten eggs → hydrogen sulfide, although sulfur compounds and odorants can smell similar.
• Garlic-like odor → organophosphates, phosphine, arsenic, selenium, or other compounds, but it is nonspecific.
• Fresh hay/musty odor → phosgene is a classic association.
• Wintergreen → methyl salicylate.
• Mothballs → naphthalene, paradichlorobenzene, or camphor.
• Paint/solvent odor → consider toluene or another volatile solvent.
• Fruity/acetone odor → consider ketosis, acetone, or isopropanol exposure.
• Always combine odor with the exposure history, physical findings, toxidrome, and targeted laboratory testing.
• Never assume an environment is safe simply because a toxic odor is no longer detectable.

Toxicology – Neuroleptic Malignant Syndrome (NMS) and Serotonin Syndrome (SS)

Definition

Neuroleptic malignant syndrome (NMS) and serotonin syndrome (SS) are potentially life-threatening hyperthermic syndromes associated with medications.

Both can cause:

• Altered mental status
• Hyperthermia
• Autonomic instability
• Abnormal muscle activity
• Rhabdomyolysis in severe cases

The major distinction is:

• NMS → dopamine blockade or withdrawal of dopaminergic therapy
• SS → excessive serotonergic activity

Their neuromuscular findings and speed of onset are particularly useful for distinguishing them.

Neuroleptic Malignant Syndrome (NMS)

NMS is primarily associated with reduced central dopaminergic activity.

Common Causes

NMS may occur after:

• Starting a dopamine antagonist
• Increasing the dose of an antipsychotic
• Using a potent dopamine-blocking medication
• Rapid dose escalation
• Abruptly stopping a dopaminergic medication

Important causative drugs include:

• Antipsychotics
• Metoclopramide
• Prochlorperazine
• Other dopamine receptor antagonists

NMS can also occur after abrupt withdrawal of drugs used to increase dopamine activity, such as levodopa.

Pathophysiology of NMS

Central dopamine receptor blockade, particularly involving D₂ receptors, interferes with:

• Hypothalamic thermoregulation
• Basal ganglia motor control
• Autonomic function

This can produce:

Dopamine blockade → severe rigidity + autonomic instability + hyperthermia + altered mental status

Severe muscle rigidity generates substantial heat and may cause extensive skeletal-muscle breakdown.

Clinical Features of NMS

The classic features are:

• Hyperthermia
• Altered mental status
• Severe generalized muscle rigidity
• Autonomic instability

Mental-status abnormalities include:

• Agitation
• Confusion
• Delirium
• Mutism
• Stupor
• Coma

Autonomic findings include:

• Tachycardia
• Hypertension
• Hypotension
• Diaphoresis
• Tachypnea
• Dysrhythmias

Muscular Findings in NMS

The characteristic finding is severe generalized “lead-pipe” rigidity.

Other extrapyramidal abnormalities may include:

• Tremor
• Bradykinesia
• Cogwheel rigidity
• Dystonia

The severe sustained muscle activity can produce:

• Elevated creatine kinase (CK)
• Rhabdomyolysis
• Hyperkalemia
• Acute kidney injury
• Hyperthermia

Laboratory Findings in NMS

Common abnormalities include:

• Markedly elevated CK
• Leukocytosis
• Elevated AST/ALT
• Metabolic acidosis
• Electrolyte abnormalities
• Myoglobinuria
• Acute kidney injury

CK elevation supports the diagnosis but is not specific for NMS.

The diagnosis remains primarily clinical.

Serotonin Syndrome

Serotonin syndrome results from excessive serotonergic activity in the CNS and peripheral nervous system.

It is usually associated with:

• Starting a serotonergic drug
• Increasing its dose
• Overdose
• Combining serotonergic medications
• Drug interactions that increase serotonin activity

Important Serotonergic Drugs

Potential causes include:

• SSRIs
• SNRIs
• MAO inhibitors
• Some tricyclic antidepressants
• Tramadol
• Dextromethorphan
• Linezolid
• Lithium
• Certain opioids with serotonergic activity
• Other serotonin-enhancing medications

The greatest risk often occurs when multiple serotonergic mechanisms are combined, especially combinations involving an MAO inhibitor.

Pathophysiology of Serotonin Syndrome

Excessive stimulation of serotonin receptors, particularly 5-HT₁A and 5-HT₂A receptors, produces the syndrome.

The characteristic clinical pattern consists of:

Mental-status changes + autonomic hyperactivity + neuromuscular hyperactivity

Mental-Status Findings in SS

Possible findings include:

• Anxiety
• Restlessness
• Agitation
• Confusion
• Delirium

Severe cases may produce:

• Seizures
• Coma

Autonomic Findings in SS

Common manifestations include:

• Diaphoresis
• Tachycardia
• Hypertension
• Hyperthermia
• Dilated pupils
• Increased bowel activity
• Diarrhea

Blood pressure can become unstable in severe cases.

Neuromuscular Findings in SS

The most important findings are:

• Clonus
• Hyperreflexia
• Tremor
• Myoclonus
• Increased muscle tone

Clonus may be:

• Spontaneous
• Inducible
• Ocular

Hyperreflexia and clonus are often particularly prominent in the lower extremities.

These findings are among the most useful clues distinguishing serotonin syndrome from NMS.

Hunter Serotonin Toxicity Criteria

Modern diagnosis commonly uses the Hunter Serotonin Toxicity Criteria rather than the older nonspecific criteria in the source.

In a patient with serotonergic exposure, serotonin toxicity is strongly supported by characteristic combinations involving:

• Spontaneous clonus
• Inducible clonus with agitation or diaphoresis
• Ocular clonus with agitation or diaphoresis
• Tremor with hyperreflexia
• Hypertonia with elevated temperature plus ocular or inducible clonus

The emphasis is therefore on clonus and hyperreflexia rather than nonspecific findings such as tachycardia alone.

Distinguishing NMS from Serotonin Syndrome

NMS

Think:

Dopamine blockade → slow onset → severe rigidity

Typical clues:

• Dopamine antagonist exposure
• Withdrawal of dopaminergic therapy
• Usually develops over days
• Severe generalized lead-pipe rigidity
• Bradykinesia
• Reflexes often normal or reduced
• Markedly elevated CK may occur
• GI hyperactivity is not characteristic

Serotonin Syndrome

Think:

Serotonin excess → rapid onset → clonus and hyperreflexia

Typical clues:

• Serotonergic medication exposure or interaction
• Usually develops within hours
• Hyperreflexia
• Clonus
• Tremor
• Myoclonus
• Diaphoresis
• Increased bowel sounds
• Diarrhea

High-Yield Distinction

NMS = rigidity + bradykinesia

SS = clonus + hyperreflexia

Onset

NMS

NMS generally develops more gradually.

Symptoms commonly evolve over approximately 1–3 days, although timing varies.

Serotonin Syndrome

Serotonin syndrome usually develops rapidly, often within hours of:

• Starting a serotonergic drug
• Increasing a dose
• Overdose
• Adding an interacting drug

Rapid onset strongly supports serotonin syndrome over NMS when the clinical findings are otherwise similar.

Hyperthermia

Both syndromes can cause dangerous hyperthermia.

The temperature elevation is largely generated by excessive skeletal-muscle activity, particularly in severe disease.

Complications include:

• Rhabdomyolysis
• Hyperkalemia
• Metabolic acidosis
• Acute kidney injury
• DIC
• Hepatic injury
• Cardiovascular collapse
• Multiorgan failure

Severe hyperthermia requires immediate treatment.

Differential Diagnosis

Other conditions that can resemble NMS or serotonin syndrome include:

• Malignant hyperthermia
• Sympathomimetic toxicity
• Anticholinergic syndrome
• MAOI toxicity
• Alcohol or sedative-hypnotic withdrawal
• Heat stroke
• Sepsis
• Meningitis/encephalitis
• Thyroid storm
• Severe agitation
• Status epilepticus
• Catatonia

The medication history and neuromuscular examination are especially important.

Malignant Hyperthermia

Malignant hyperthermia is usually triggered during anesthesia by:

• Certain volatile anesthetic agents
• Succinylcholine

Features include:

• Rapidly increasing CO₂ production
• Muscle rigidity
• Acidosis
• Hyperkalemia
• Rhabdomyolysis
• Hyperthermia

Dantrolene is the specific treatment for malignant hyperthermia.

It should not be confused with NMS merely because both conditions can involve rigidity and hyperthermia.

Sympathomimetic Toxicity

Stimulant poisoning can cause:

• Agitation
• Tachycardia
• Hypertension
• Mydriasis
• Diaphoresis
• Hyperthermia
• Tremor
• Seizures

However, the characteristic clonus and marked hyperreflexia of serotonin syndrome are generally absent.

Anticholinergic Syndrome

Anticholinergic toxicity can cause:

• Hyperthermia
• Agitated delirium
• Tachycardia
• Mydriasis

A useful clue is:

Anticholinergic → hot and dry

whereas serotonin syndrome commonly produces diaphoresis and increased bowel activity.

Diagnostic Evaluation

There is no single laboratory test that confirms either NMS or serotonin syndrome.

Evaluation should include:

• Detailed medication history
• Recent dose changes
• Drug interactions
• Neurologic examination
• Reflex examination
• Assessment for clonus
• Core temperature
• Hydration and perfusion status

Laboratory Tests

Important investigations in significant cases include:

• CK
• Electrolytes
• Glucose
• Renal function
• Liver enzymes
• CBC
• Blood gas when indicated
• Lactate
• Urinalysis
• ECG

Urinalysis may show evidence of myoglobinuria from rhabdomyolysis.

Other tests should be directed toward alternative diagnoses when necessary.

Management of Both Syndromes

Initial management includes:

• Stop the causative medication.
• Stabilize airway and breathing.
• Establish IV access.
• Begin cardiac monitoring.
• Monitor core temperature.
• Correct dehydration and electrolyte abnormalities.
• Control agitation.
• Treat seizures.
• Actively cool significant hyperthermia.

Severe cases require intensive monitoring.

Benzodiazepines

Benzodiazepines are particularly useful for:

• Agitation
• Tremor
• Seizures
• Excessive muscle activity

They can also decrease heat generation by reducing agitation and muscular activity.

They are especially important in serotonin syndrome.

Cooling

Hyperthermia should be treated with physical cooling, such as:

• Evaporative cooling
• Fans
• Other active external cooling measures

Antipyretics such as acetaminophen are generally ineffective because the temperature elevation is not caused by an increased hypothalamic set point.

Severe Hyperthermia

Extreme hyperthermia caused by sustained muscle activity may require:

• Deep sedation
• Endotracheal intubation
• Mechanical ventilation
• Neuromuscular paralysis

A nondepolarizing neuromuscular blocker is generally preferred when paralysis is required.

Rapid control of muscle activity is essential because continued rigidity can generate enormous amounts of heat.

Treatment of NMS

The most important intervention is:

Immediately stop the dopamine-blocking medication.

Supportive treatment includes:

• IV fluids when appropriate
• Cooling
• Correction of electrolyte abnormalities
• Treatment of rhabdomyolysis
• Management of renal complications
• Benzodiazepines

Most treatment is fundamentally supportive.

Dantrolene in NMS

Dantrolene reduces skeletal-muscle contraction and may be considered in selected severe NMS cases.

Evidence for its benefit in NMS is less established than for malignant hyperthermia.

It should therefore be regarded as an adjunct in selected severe cases, not a universal antidote for NMS.

Bromocriptine in NMS

Bromocriptine is a dopamine agonist that may be considered in selected moderate-to-severe NMS cases.

Other dopaminergic strategies may occasionally be used under specialist guidance.

Again, supportive care and removal of the offending drug remain central.

Treatment of Serotonin Syndrome

The first step is:

Stop all serotonergic medications.

Most mild-to-moderate cases improve with:

• Discontinuation of serotonergic drugs
• Benzodiazepines
• IV fluids when required
• Cooling
• Supportive care

Because many serotonergic drugs have relatively short effective durations, improvement can occur relatively quickly once the responsible agents are stopped.

Cyproheptadine

Cyproheptadine is a serotonin antagonist that may be considered in moderate or severe serotonin syndrome when supportive treatment and benzodiazepines are insufficient.

It is administered enterally rather than intravenously.

Evidence is largely based on clinical experience rather than high-quality randomized trials.

Blood Pressure Abnormalities

Both syndromes may produce:

• Hypertension
• Hypotension
• Rapid blood-pressure fluctuations

Hypertension often improves when:

• Agitation is controlled
• Rigidity decreases
• Hyperthermia is treated

Persistent severe abnormalities should be treated with short-acting, titratable agents appropriate to the patient’s hemodynamic state.

The source’s routine dopamine-first approach for hypotension is outdated; vasopressor choice should reflect the mechanism and current critical-care practice.

Rhabdomyolysis

Severe rigidity and hyperthermia can produce extensive skeletal-muscle breakdown.

Monitor:

• CK
• Potassium
• Creatinine
• Urine output
• Acid-base status

Complications include:

• Hyperkalemia
• Acute kidney injury
• Dysrhythmias

Decontamination

Do not induce vomiting.

Routine gastric lavage is not recommended.

Activated charcoal may be considered only after selected recent ingestions when:

• The drug is adsorbed by charcoal,
• Clinically significant toxicity is expected, and
• The airway can be safely protected.

Decontamination must never delay treatment of hyperthermia, seizures, rigidity, or cardiovascular instability.

Monitoring

Severe NMS or serotonin syndrome requires close monitoring of:

• Core temperature
• Mental status
• Cardiac rhythm
• Blood pressure
• Respiratory function
• CK
• Electrolytes
• Renal function
• Urine output

Patients with severe hyperthermia, rigidity, cardiovascular instability, seizures, or organ dysfunction generally require intensive-care management.

Expected Course

NMS

NMS generally:

• Develops more slowly
• Lasts longer
• May take days to resolve after the responsible drug is discontinued

Long-acting or depot antipsychotic exposure may prolong the syndrome.

Serotonin Syndrome

Serotonin syndrome generally:

• Begins rapidly
• Improves more rapidly after serotonergic drugs are stopped

Many uncomplicated cases improve substantially within about a day, although toxicity from long-acting agents or active metabolites can persist longer.

Key Points

• NMS and serotonin syndrome can both cause hyperthermia, altered mental status, autonomic instability, and abnormal muscle activity.
• NMS is associated with dopamine blockade or withdrawal of dopaminergic therapy.
• Serotonin syndrome results from excessive serotonergic activity.
• NMS generally has a slower onset with severe generalized rigidity and bradykinesia.
• Serotonin syndrome generally has a rapid onset with hyperreflexia and clonus.
• Clonus is one of the most useful findings suggesting serotonin syndrome.
• Diarrhea and increased bowel activity favor serotonin syndrome.
• Marked CK elevation and severe sustained rigidity are particularly characteristic of NMS, although they are not exclusive to it.
• The Hunter Serotonin Toxicity Criteria are commonly used to diagnose serotonin toxicity.
• Both syndromes can cause rhabdomyolysis, hyperkalemia, AKI, dysrhythmias, and multiorgan failure.
• Stop the causative medication immediately.
• Benzodiazepines, supportive care, and aggressive temperature control are central treatments.
• Cyproheptadine may be considered for significant serotonin syndrome.
• Dantrolene or bromocriptine may be considered in selected severe NMS cases.
• Antipyretics generally do not correct the hyperthermia because excessive muscle activity—not a raised hypothalamic set point—is the primary problem.
• Severe hyperthermia requires rapid control because prolonged extreme temperature can itself cause life-threatening organ injury.

Toxicology – Multiple Chemical Sensitivity (MCS)

Definition

Multiple chemical sensitivity (MCS) describes a syndrome in which a person reports recurrent symptoms involving multiple organ systems after exposure to low concentrations of various environmental chemicals.

The term is controversial because these exposures are typically below concentrations expected to cause direct toxic effects, and no specific toxicologic mechanism or diagnostic biomarker has been established.

The term idiopathic environmental intolerance (IEI) is also commonly used because it describes the clinical phenomenon without assuming that chemical toxicity is the underlying mechanism.

Typical Pattern

Features traditionally associated with MCS/IEI include:

• Symptoms beginning after a perceived environmental or occupational exposure
• Symptoms involving several organ systems
• Recurrence with particular environmental triggers
• Symptoms attributed to chemically unrelated substances
• Reactions occurring at concentrations below established toxic thresholds
• Improvement after leaving the triggering environment

Frequently reported triggers include:

• Perfumes and fragrances
• Cleaning products
• Solvents
• Pesticides
• Vehicle exhaust
• Paints
• Smoke
• Other strongly scented or irritating substances

Pathophysiology

There is no established single pathophysiologic mechanism that explains MCS/IEI.

Proposed mechanisms have included:

• Altered sensory processing
• Neurobiologic mechanisms
• Autonomic responses
• Stress-response pathways
• Conditioning or learned responses
• Psychological and psychophysiologic mechanisms
• Immunologic mechanisms

However, a reproducible pattern of:

• Immune dysfunction
• Toxicant accumulation
• Specific biochemical abnormalities
• Organ injury

has not been demonstrated consistently enough to serve as a diagnostic explanation.

Important Clinical Principle

The absence of a demonstrated toxicologic mechanism does not mean that the patient’s symptoms are fabricated.

Symptoms can be genuine and functionally significant even when conventional examination and laboratory testing do not identify a specific toxic injury.

The clinical task is therefore to:

Validate the symptoms → investigate plausible medical/toxicologic causes → avoid unsupported causal conclusions → provide evidence-based symptom management

Epidemiology

The exact prevalence depends heavily on how MCS/IEI is defined.

Historically, many clinical series have reported a predominance of women.

Symptoms may be mild in some patients but can substantially interfere with:

• Employment
• Social activities
• Travel
• Use of public spaces
• Daily functioning

Triggering Events

Some patients describe onset after:

• Occupational chemical exposure
• Irritant-gas exposure
• Solvent exposure
• Pesticide exposure
• Building-related exposure
• Other environmental events

Later, symptoms may be attributed to much smaller exposures and to substances chemically unrelated to the original trigger.

A reported initiating exposure should be evaluated on its own merits rather than automatically assumed to have caused chronic systemic toxicity.

Clinical Features

Symptoms are usually nonspecific and multisystemic.

Common complaints include:

Neurologic/general

• Headache
• Fatigue
• Difficulty concentrating
• Subjective memory problems
• Dizziness
• Weakness
• Tremor
• Paresthesias
• Sleep disturbance

Respiratory/ENT

• Nasal irritation or congestion
• Throat discomfort
• Cough
• Dyspnea
• Chest tightness
• Sensitivity to odors

Cardiovascular

• Palpitations
• Chest discomfort

Gastrointestinal

• Nausea
• Abdominal discomfort
• Appetite changes
• Altered bowel habits

Dermatologic

• Pruritus
• Rash
• Dryness

Psychological symptoms such as anxiety or low mood may coexist, but their presence does not by itself establish the cause of the overall syndrome.

Physical Examination

There is no characteristic physical finding that confirms MCS/IEI.

The examination is instead important for detecting alternative explanations.

Particular attention should be given to:

• Neurologic abnormalities
• Respiratory disease
• Dermatologic findings
• Cardiovascular abnormalities
• Thyroid findings
• Signs of systemic inflammatory disease
• Objective evidence of a specific toxic exposure

Differential Diagnosis

Before attributing symptoms to MCS/IEI, consider established medical disorders capable of producing similar complaints.

Examples include:

• Asthma
• Allergic rhinitis
• Migraine
• Thyroid disease
• Anemia
• Sleep disorders
• Autoimmune/inflammatory disease
• Neurologic disease
• Medication adverse effects
• Anxiety or panic disorders
• Depression
• Other causes of chronic fatigue or cognitive symptoms

A genuine occupational or environmental exposure should also be investigated when the history supports one.

Specific Toxic Exposures

Potential exposures sometimes attributed to MCS include:

• Heavy metals
• Solvents
• Pesticides
• Formaldehyde
• Irritant gases

These should not be diagnosed merely from nonspecific symptoms.

A specific poisoning diagnosis requires a plausible combination of:

Exposure history + dose/intensity + timing + expected clinical syndrome ± appropriate objective testing

Diagnostic Approach

There is currently no single laboratory test, imaging study, allergy test, or biomarker that establishes MCS/IEI.

Evaluation begins with a detailed history covering:

• Initial triggering event
• Specific suspected substances
• Exposure route
• Duration and intensity
• Temporal relationship between exposure and symptoms
• Occupational environment
• Medication history
• Medical history
• Pattern of symptom recurrence
• Functional impact

Laboratory Testing

Testing should be targeted to the clinical presentation, rather than applying a large universal panel to every patient.

Depending on symptoms, reasonable evaluation may include:

• CBC
• Electrolytes
• Glucose
• Renal function
• Liver tests
• Thyroid studies

Additional investigations should be guided by specific clinical findings.

Heavy-Metal Testing

Heavy-metal testing should be performed when there is a credible exposure history or compatible clinical syndrome.

Indiscriminate screening can produce misleading results because detectable amounts of many metals may occur without clinical poisoning.

Provoked urine metal testing after administration of a chelator is not an accepted method for diagnosing chronic heavy-metal poisoning.

Allergy and Immune Testing

MCS/IEI should not automatically be interpreted as an allergic disorder.

Conventional allergy evaluation is appropriate when symptoms suggest:

• Asthma
• Allergic rhinitis
• Urticaria
• Anaphylaxis
• Another established hypersensitivity disorder

Broad unconventional immune panels have not been shown to diagnose MCS reliably.

Treatment

There is no specific antidote or universally established pharmacologic treatment for MCS/IEI.

Management should focus on:

• Identifying and treating established medical conditions
• Managing individual symptoms
• Maintaining daily function
• Addressing occupational concerns
• Avoiding unnecessary medications or procedures
• Providing consistent longitudinal medical care

Exposure Reduction

Avoiding a substance that causes documented irritation, allergy, or toxicity is appropriate.

However, increasingly restrictive avoidance of extremely low-level everyday environmental exposures can sometimes lead to:

• Social isolation
• Occupational disability
• Reduced physical activity
• Increasing sensitivity or fear surrounding ordinary environments

Management should therefore balance reasonable exposure reduction with preservation of normal function.

Psychological and Behavioral Treatment

When symptoms are associated with anxiety, conditioned responses, stress, or significant functional impairment, interventions such as:

• Cognitive behavioral approaches
• Stress-management strategies
• Treatment of anxiety or depression when present
• Gradual rehabilitation

may be useful.

These interventions should be presented as methods for reducing symptoms and improving function, not as evidence that symptoms are imaginary.

Occupational Management

When symptoms occur at work, an occupational and environmental medicine evaluation can help determine:

• What substances are actually present
• Whether concentrations are potentially hazardous
• Whether coworkers are affected
• Whether ventilation is adequate
• Whether exposure controls are indicated

Objective exposure assessment is preferable to assuming either that the workplace is toxic or that the exposure is irrelevant.

Treatments to Avoid

Without evidence of a specific indication, avoid:

• Empiric chelation
• Unvalidated “detoxification” regimens
• Extreme elimination diets
• Unsupported immune therapies
• Repeated unnecessary laboratory panels
• Unvalidated chemical-provocation testing
• Excessively restrictive environmental avoidance

These approaches may cause direct harm, reinforce disability, or delay diagnosis of another medical disorder.

Acute Exposure

If a patient with a history of MCS presents after a new substantial chemical exposure, that event should be evaluated as a possible acute poisoning on its own merits.

Do not assume that new symptoms are simply part of MCS.

Conversely, the presence of symptoms after detecting an odor does not by itself establish toxic exposure.

Decontamination

There is no routine decontamination procedure for MCS/IEI.

Decontamination is appropriate only when there has been a specific acute exposure requiring it.

Gastric decontamination has no role merely because chronic symptoms are attributed to environmental chemicals.

Prognosis

The course is variable.

Symptoms may:

• Resolve
• Fluctuate
• Recur with perceived triggers
• Persist chronically

For some patients, functional impairment becomes more significant than measurable physiologic abnormalities.

A stable therapeutic relationship and emphasis on function, symptom control, and appropriate investigation are important.

Key Points

• MCS describes recurrent multisystem symptoms attributed to low-level exposure to multiple chemically unrelated substances.
• Idiopathic environmental intolerance (IEI) is a commonly used alternative term that avoids assuming a proven toxic mechanism.
• No reproducible biochemical, immunologic, or toxicologic abnormality has been established as a universal explanation.
• There is no diagnostic biomarker or specific antidote.
• Symptoms can be genuine and disabling even when objective evidence of toxic injury is absent.
• Do not automatically attribute symptoms either to chemical toxicity or to psychiatric disease.
• Specific poisoning requires a credible exposure history, appropriate timing, compatible clinical findings, and targeted testing when available.
• Laboratory testing should be guided by the presentation rather than broad indiscriminate screening.
• Provoked urine heavy-metal testing and empiric chelation are not appropriate diagnostic or therapeutic approaches.
• Treat identifiable medical disorders and individual symptoms while supporting normal function.
• Reasonable exposure control is appropriate, but extreme avoidance of ordinary low-level environmental exposures can itself become functionally harmful.
• A new significant exposure should always be evaluated independently rather than automatically attributed to the pre-existing MCS/IEI label.

Toxicology – Movement Disorders

Definition

Abnormal movements can provide important clues to the cause of poisoning or medication toxicity.

Toxicologic movement disorders include:

• Akathisia
• Asterixis
• Myoclonus
• Ataxia
• Chorea
• Dystonia
• Dysarthria
• Fasciculations
• Nystagmus
• Drug-induced parkinsonism
• Rigidity
• Tremor
• Tardive dyskinesia

Recognition of the movement pattern + medication/exposure history + associated toxidrome is usually more useful than the movement abnormality alone.

Akathisia

Akathisia is a subjective feeling of inner restlessness accompanied by an inability to remain still.

Patients may:

• Pace
• Rock back and forth
• Repeatedly cross and uncross their legs
• Constantly shift position
• Report intense internal restlessness

It may be mistaken for anxiety, agitation, or worsening psychiatric illness.

Common drug causes include:

• Antipsychotics
• Metoclopramide and other dopamine-antagonist antiemetics
• Some antidepressants
• Other dopamine-blocking drugs

Symptoms often follow initiation or an increase in dose.

Asterixis

Asterixis is a negative myoclonus caused by brief interruptions of sustained muscle contraction.

When the arms and wrists are extended, there are intermittent lapses of posture producing the characteristic “flapping” movement.

Toxicologic causes include:

• Sedative-hypnotics
• Anticonvulsants
• Some psychoactive medications

Important nontoxic causes include:

• Hepatic encephalopathy
• Uremia
• Hypercapnia
• Other metabolic encephalopathies

Myoclonus

Myoclonus consists of brief, sudden, shock-like involuntary movements.

Unlike asterixis, classic positive myoclonus results from sudden muscle contraction.

Drug-related causes include:

• Serotonergic medications
• Opioids
• Anticonvulsants
• Lithium
• Some antidepressants
• Sedative-hypnotics

Myoclonus accompanied by hyperreflexia and clonus should raise concern for serotonin toxicity.

Ataxia

Ataxia is impaired coordination of voluntary movement.

Manifestations include:

• Unsteady gait
• Difficulty standing
• Poor limb coordination
• Dysmetria
• Impaired balance

Common toxicologic causes include:

• Ethanol
• Benzodiazepines
• Barbiturates
• Anticonvulsants
• Lithium
• Sedating antihistamines
• Other CNS depressants

Phenytoin and Ataxia

Phenytoin toxicity classically produces a progression of neurologic abnormalities such as:

• Nystagmus
• Ataxia
• Dysarthria
• Tremor
• Increasing CNS depression at higher exposure

These findings can be particularly useful when correlated with the clinical history and serum phenytoin concentration.

Chorea

Chorea consists of irregular, unpredictable, nonrhythmic movements that seem to flow randomly from one body region to another.

Very forceful choreiform movements are sometimes termed ballism.

Toxic or medication-related causes include:

• Dopaminergic medications
• Stimulants
• Antipsychotic-related movement disorders
• Lithium
• Carbon monoxide
• Manganese
• Some anticonvulsants

Metabolic causes include:

• Hypoglycemia or hyperglycemia
• Sodium abnormalities
• Calcium abnormalities
• Hyperthyroidism

Neurologic alternatives include Huntington disease and Wilson disease.

Dystonia

Dystonia consists of sustained or intermittent muscle contractions producing abnormal movements or postures.

Acute drug-induced dystonia commonly affects the:

• Face
• Eyes
• Jaw
• Tongue
• Neck

Manifestations include:

• Oculogyric crisis – forced upward or lateral eye deviation
• Torticollis – abnormal neck turning
• Retrocollis – backward neck extension
• Jaw spasm
• Tongue protrusion
• Blepharospasm
• Dysarthria
• Dysphagia
• Opisthotonic posturing

Acute Dystonic Reaction

The classic causes are dopamine D₂-receptor antagonists, especially:

• Antipsychotics
• Metoclopramide
• Prochlorperazine
• Other dopamine-blocking antiemetics

Acute dystonia can be dramatic and frightening but usually responds rapidly to an anticholinergic medication such as diphenhydramine or benztropine.

Rare laryngeal dystonia can compromise the airway and requires urgent treatment.

Dysarthria

Dysarthria is impaired articulation caused by poor motor control of the muscles involved in speech.

Speech may become:

• Slurred
• Slow
• Poorly articulated

Toxic causes include:

• Ethanol
• Sedative-hypnotics
• Anticonvulsants
• Lithium
• Other CNS-depressant drugs

Dysarthria often accompanies ataxia and nystagmus in sedative or anticonvulsant toxicity.

Fasciculations

Fasciculations are visible, brief contractions of individual motor units.

Important toxicologic causes include:

• Organophosphates
• Carbamates
• Nicotine
• Some stimulants
• Certain neurotoxins

In organophosphate poisoning, fasciculations represent nicotinic acetylcholine receptor overstimulation and may progress to:

• Muscle weakness
• Paralysis
• Respiratory failure

When accompanied by miosis, bronchorrhea, salivation, sweating, and diarrhea, a cholinergic syndrome should be strongly suspected.

Nystagmus

Nystagmus is rhythmic involuntary movement of the eyes.

Toxicologic causes include:

• Sedative-hypnotics
• Anticonvulsants
• Lithium
• Phencyclidine (PCP)
• Ethanol

The direction and pattern can sometimes provide additional clues.

PCP and Nystagmus

PCP intoxication is classically associated with:

• Horizontal, vertical, or rotatory nystagmus
• Agitation or unusual behavior
• Analgesia
• Hypertension
• Tachycardia
• Ataxia

Vertical nystagmus in an intoxicated patient is an especially useful clue, although it is not completely specific.

Parkinsonism

Drug-induced parkinsonism resembles Parkinson disease and may produce:

• Bradykinesia
• Rigidity
• Tremor
• Shuffling gait
• Reduced facial expression
• Postural instability

The major medication mechanism is dopamine D₂ receptor blockade.

Common causes include:

• Antipsychotics
• Metoclopramide
• Prochlorperazine
• Other dopamine antagonists

Toxic Parkinsonism

Toxic exposures associated with parkinsonian syndromes include:

• Manganese
• Carbon monoxide
• Methanol
• Carbon disulfide
• MPTP

MPTP is particularly notable because its toxic metabolite selectively damages dopaminergic neurons in the substantia nigra and can produce profound parkinsonism.

Rigidity

Rigidity is increased resistance to passive movement.

In toxicology, marked rigidity accompanied by hyperthermia and altered mental status should immediately raise concern for:

• Neuroleptic malignant syndrome
• Serotonin syndrome
• Malignant hyperthermia
• Severe MAOI toxicity

The accompanying neuromuscular findings help differentiate them.

NMS vs. Serotonin Syndrome

Neuroleptic malignant syndrome

• Dopamine blockade or withdrawal of dopaminergic therapy
• Usually slower onset
• Severe generalized rigidity
• Hyporeflexia or relatively normal reflexes
• Hyperthermia
• Autonomic instability
• Altered mental status
• Elevated CK

Serotonin syndrome

• Serotonergic exposure
• Usually rapid onset
• Hyperreflexia
• Clonus
• Tremor
• Agitation
• Diaphoresis
• Hyperthermia
• GI hyperactivity may occur

The presence of clonus strongly favors serotonin toxicity.

Tremor

Tremor is a rhythmic oscillating movement.

It may be classified as:

• Resting
• Postural
• Kinetic/action

Important toxicologic causes include:

• Lithium
• Valproate
• Stimulants
• Caffeine
• Beta₂-adrenergic agonists
• Theophylline
• Thyroid hormone excess
• Heavy metals
• Alcohol or sedative withdrawal

The pattern of tremor alone rarely identifies the toxicant, so associated findings are essential.

Lithium

Lithium toxicity can produce multiple movement abnormalities, including:

• Coarse tremor
• Ataxia
• Dysarthria
• Myoclonus
• Fasciculations
• Nystagmus
• Chorea in severe cases

Progressive neurologic abnormalities in a patient taking lithium should prompt assessment for toxicity.

Tardive Dyskinesia

Tardive dyskinesia is a delayed hyperkinetic movement disorder associated primarily with prolonged exposure to dopamine receptor-blocking medications.

Typical manifestations include:

• Lip smacking
• Chewing movements
• Grimacing
• Tongue protrusion
• Repetitive facial movements
• Limb or trunk movements

Unlike acute dystonia, tardive dyskinesia usually develops after chronic exposure.

Symptoms can persist after the responsible medication is discontinued.

Tardive Dystonia

Tardive dystonia is another delayed complication of chronic dopamine receptor blockade.

It causes sustained abnormal postures and may involve:

• Neck
• Trunk
• Limbs
• Cranial muscles

It should be distinguished from an acute dystonic reaction, which generally appears shortly after beginning or increasing a dopamine-blocking medication.

Extrapyramidal Syndromes

A useful framework for dopamine-blocking medication effects is:

Hours to days

→ acute dystonia

Days to weeks

→ akathisia

Weeks to months

→ drug-induced parkinsonism

Months to years

→ tardive dyskinesia/tardive dystonia

The timing is approximate and overlap can occur.

Diagnostic Approach

When an abnormal movement occurs, determine:

• Exact type of movement
• Time of onset
• Recent medication changes
• Prescription and nonprescription drug exposure
• Withdrawal history
• Occupational or heavy-metal exposure
• Associated mental-status changes
• Autonomic findings
• Temperature
• Reflexes and clonus

The time relationship between drug exposure and movement onset is particularly useful.

Laboratory Evaluation

Testing should be guided by the suspected cause.

Possible investigations include:

• Glucose
• Electrolytes
• Calcium and magnesium
• Renal function
• Liver function
• Creatine kinase
• ECG

Targeted testing may include:

• Lithium concentration
• Anticonvulsant concentrations
• Heavy-metal testing when exposure is plausible
• Other drug-specific studies

Broad urine toxicology screening is usually less useful than targeted evaluation.

Neuroimaging

Movement disorders should not automatically be attributed to poisoning.

Brain imaging may be necessary when findings suggest:

• Stroke
• Intracranial hemorrhage
• Structural CNS disease
• Trauma
• Focal neurologic abnormalities

Management Principles

Treatment depends on the underlying syndrome.

General measures include:

• Stop or modify the causative medication when appropriate.
• Correct glucose and electrolyte abnormalities.
• Treat hyperthermia.
• Control seizures.
• Provide supportive care.

Important syndrome-specific treatments include:

Acute dystonia

→ diphenhydramine or benztropine

Akathisia

→ remove/reduce the causative agent when appropriate; selected symptomatic therapies may be used

Serotonin syndrome

→ discontinue serotonergic drugs, benzodiazepines, cooling, and selected use of cyproheptadine

NMS

→ discontinue dopamine antagonist, supportive care/cooling, with syndrome-specific therapy in severe cases

Cholinergic fasciculations

→ atropine for muscarinic manifestations plus pralidoxime in significant organophosphate poisoning

Tardive Dyskinesia Treatment

Management includes reassessing the responsible dopamine-blocking medication.

VMAT2 inhibitors such as valbenazine or deutetrabenazine are established treatments for clinically significant tardive dyskinesia.

Routine anticholinergic treatment may worsen tardive dyskinesia, even though anticholinergics are useful for acute dystonia and drug-induced parkinsonism.

Key Points

• Abnormal movements can provide important toxicologic diagnostic clues.
• Akathisia = inner restlessness with inability to remain still.
• Asterixis = brief loss of postural tone; myoclonus = sudden shock-like movement.
• Ethanol, sedatives, anticonvulsants, and lithium commonly produce ataxia.
• Dopamine-blocking antipsychotics and antiemetics commonly cause acute dystonia, akathisia, and parkinsonism.
• Acute dystonia commonly involves the eyes, jaw, tongue, and neck and usually responds to anticholinergic treatment.
• Fasciculations + excessive secretions + miosis strongly suggest cholinergic toxicity.
• PCP classically produces prominent nystagmus, including vertical nystagmus.
• Rigidity + hyperthermia should prompt consideration of NMS, serotonin syndrome, or malignant hyperthermia.
• Clonus and hyperreflexia strongly favor serotonin syndrome over NMS.
• Lithium toxicity can produce coarse tremor, ataxia, dysarthria, myoclonus, and other neurologic abnormalities.
• Tardive dyskinesia is a delayed complication of chronic dopamine-receptor blockade and may persist after drug discontinuation.
• Always consider metabolic and structural neurologic disease before assuming that an abnormal movement is toxicologic.

Toxicology – Methemoglobinemia

Definition

Methemoglobinemia occurs when hemoglobin iron is oxidized from its normal ferrous (Fe²⁺) state to the ferric (Fe³⁺) state.

Ferric hemoglobin, called methemoglobin (MetHb), cannot effectively bind oxygen.

Normally, MetHb represents approximately <1–2% of total hemoglobin.

Pathophysiology

Methemoglobinemia impairs oxygen delivery by two mechanisms:

1. Methemoglobin itself cannot carry oxygen effectively.
2. Methemoglobin increases the oxygen affinity of the remaining normal hemoglobin, shifting the oxyhemoglobin dissociation curve to the left.

Therefore:

Oxidation of Fe²⁺ → Fe³⁺ → reduced O₂-carrying capacity + impaired O₂ unloading → tissue hypoxia

This produces a form of functional anemia despite a potentially normal measured hemoglobin concentration and PaO₂.

Normal Reduction of Methemoglobin

Small amounts of methemoglobin are continuously generated and normally converted back to functional hemoglobin.

The major pathway uses:

Cytochrome b₅ reductase (NADH-dependent methemoglobin reductase)

A secondary NADPH-dependent pathway normally contributes little but becomes clinically important when methylene blue is administered.

Methylene Blue Mechanism

Methylene blue acts as an electron carrier.

In the presence of NADPH, it is converted to leucomethylene blue, which accelerates reduction of:

Fe³⁺ → Fe²⁺

NADPH production depends heavily on the pentose phosphate pathway and G6PD, explaining why methylene blue may be ineffective or harmful in significant G6PD deficiency.

Causes

Most acquired cases result from exposure to an oxidizing medication or chemical.

Important causes include:

• Benzocaine
• Prilocaine
• Dapsone
• Nitrates
• Nitrites
• Amyl/alkyl nitrites
• Aniline compounds
• Phenazopyridine
• Primaquine
• Sulfonamides
• Nitroglycerin and related nitrates
• Some industrial oxidizing chemicals

Benzocaine and dapsone are particularly important toxicologic causes.

Dapsone

Dapsone is notable because its metabolites are potent oxidants.

Toxicity may produce:

• Significant methemoglobinemia
• Hemolysis
• Recurrent or prolonged methemoglobinemia

Because of its pharmacokinetics and enterohepatic/enteric recycling, clinically important methemoglobinemia can recur after initial improvement.

Nitrites and Nitrates

Nitrites directly oxidize hemoglobin.

Nitrates can be converted to nitrites and may therefore produce methemoglobinemia.

Potential exposures include:

• Contaminated water
• Certain foods or chemicals
• Medications
• Recreational inhaled nitrites

Infants are particularly susceptible.

Infants

Young infants have increased susceptibility because:

• Fetal hemoglobin is more readily oxidized.
• Methemoglobin-reducing enzyme activity is relatively immature.
• Certain gastrointestinal conditions may increase nitrite production.

Thus, relatively modest oxidant exposure may cause more clinically important methemoglobinemia in infants.

Congenital Methemoglobinemia

Congenital causes include:

• Cytochrome b₅ reductase deficiency
• Hemoglobin M variants

Patients with congenital disease may have chronic cyanosis despite otherwise relatively few symptoms, depending on the specific disorder.

G6PD Deficiency

G6PD deficiency does not represent the usual mechanism of methemoglobinemia itself, but it is extremely important when choosing treatment.

Reduced G6PD activity limits production of NADPH.

Consequently, methylene blue may:

• Work poorly
• Increase oxidative stress
• Cause or worsen hemolysis

Significant G6PD deficiency therefore complicates treatment.

Clinical Features

Symptoms depend on:

• Methemoglobin concentration
• Rate of development
• Baseline hemoglobin
• Cardiopulmonary reserve
• Other causes of impaired oxygen delivery

Common manifestations include:

• Cyanosis
• Headache
• Fatigue
• Dizziness
• Dyspnea
• Tachycardia
• Tachypnea

More severe toxicity may cause:

• Confusion
• Syncope
• Chest pain
• Hypotension
• Dysrhythmias
• Seizures
• Coma
• Cardiovascular collapse

Cyanosis

Cyanosis is one of the classic findings.

It is often described as slate-gray, blue-gray, or brownish and may persist despite supplemental oxygen.

A patient with:

Persistent cyanosis + relatively preserved PaO₂ + unusual pulse-oximetry findings

should raise strong suspicion for dyshemoglobinemia.

Chocolate-Brown Blood

Blood containing substantial methemoglobin may appear dark or chocolate brown rather than normally bright red.

This appearance is a useful clue but does not replace laboratory confirmation.

Severity and MetHb Level

Symptoms generally become more likely as the MetHb percentage rises, but rigid concentration thresholds are unreliable.

Broadly:

• Low levels: often asymptomatic
• Moderate levels: cyanosis, headache, dizziness, fatigue, dyspnea
• Higher levels: confusion, syncope, chest pain, marked hypoxia symptoms
• Severe levels: seizures, dysrhythmias, shock, coma
• Very high levels: potentially fatal

Treatment should therefore be based on the patient’s symptoms, MetHb concentration, underlying disease, and ongoing oxidant exposure, rather than concentration alone.

Higher-Risk Patients

Symptoms can develop at lower MetHb concentrations in patients with:

• Anemia
• Coronary artery disease
• Heart failure
• Significant pulmonary disease
• Sepsis or shock
• Other conditions reducing oxygen delivery

Pregnancy and infancy also warrant particular caution.

Pulse Oximetry

Standard two-wavelength pulse oximetry is unreliable in methemoglobinemia.

As MetHb rises, the displayed oxygen saturation tends to drift toward approximately the mid-80% range, often around 85%, regardless of the actual arterial oxygen content.

Thus, an SpO₂ that remains near the mid-80s despite oxygen therapy is a classic clue.

PaO₂ Can Be Normal

A major diagnostic pitfall is assuming that a normal arterial PaO₂ excludes serious hypoxia.

PaO₂ measures oxygen dissolved in plasma.

It does not directly measure how much oxygen hemoglobin is actually carrying.

Therefore:

Methemoglobinemia → normal/high PaO₂ may coexist with severely impaired hemoglobin-mediated oxygen delivery

Saturation Gap

A saturation gap may occur when:

• Calculated arterial oxygen saturation from a blood gas appears normal or high,
• while pulse oximetry shows substantially lower saturation.

This discrepancy should raise suspicion for a dyshemoglobinemia such as:

• Methemoglobinemia
• Carboxyhemoglobinemia

However, direct co-oximetry is preferred for diagnosis.

Co-Oximetry

Co-oximetry is the diagnostic test of choice.

Unlike ordinary pulse oximetry, it uses multiple wavelengths to distinguish:

• Oxyhemoglobin
• Deoxyhemoglobin
• Methemoglobin
• Carboxyhemoglobin

The MetHb percentage should therefore be directly measured, not inferred from standard oxygen saturation.

Evaluation

Important investigations include:

• Co-oximetry with MetHb measurement
• ECG
• CBC
• Electrolytes
• Renal function
• Blood gas when clinically indicated

Depending on severity or suspected toxicant:

• Lactate
• Hemolysis studies
• Liver tests
• Targeted toxicology testing

G6PD testing may be useful but generally should not delay emergency management.

Hemolysis

Some oxidant exposures can cause both:

• Methemoglobinemia
• Oxidative hemolytic anemia

This is particularly relevant with agents such as:

• Dapsone
• Naphthalene
• Primaquine
• Other strong oxidants

Evidence of hemolysis may include:

• Falling hemoglobin
• Elevated bilirubin
• Elevated LDH
• Reduced haptoglobin
• Abnormal peripheral smear

Initial Management

The first steps are:

• Stop exposure to the causative agent.
• Support airway and ventilation as necessary.
• Administer supplemental oxygen.
• Obtain co-oximetry.
• Assess for cardiovascular or neurologic evidence of tissue hypoxia.

Supplemental oxygen does not directly convert methemoglobin back to normal hemoglobin, but it maximizes oxygenation of the remaining functional hemoglobin.

Methylene Blue

Methylene blue is the standard antidote for clinically significant acquired methemoglobinemia.

It is particularly considered when there is:

• Significant symptomatic methemoglobinemia
• Neurologic dysfunction
• Cardiovascular manifestations
• Significant or rising MetHb concentration

Patients with impaired oxygen-delivery reserve may warrant treatment at a lower MetHb level than otherwise healthy patients.

Important Methylene Blue Precautions

Methylene blue requires caution in G6PD deficiency because adequate NADPH production is required for its therapeutic action.

It can also cause oxidative hemolysis.

Excessive methylene blue exposure can paradoxically act as an oxidant and worsen methemoglobinemia.

Therefore, repeated treatment should not continue automatically when the patient fails to respond as expected.

Methylene Blue and Serotonin Toxicity

An important modern safety consideration is that methylene blue has monoamine oxidase-A inhibitory activity.

In patients receiving serotonergic medications, it can precipitate serotonin toxicity, particularly with substantial systemic exposure.

When methylene blue is urgently required for life-threatening methemoglobinemia, the immediate oxygen-delivery problem must still be addressed, but serotonergic medications and interaction risk should be reviewed.

When Methylene Blue Fails

Failure to improve should prompt consideration of:

• G6PD deficiency
• Continued oxidant absorption
• Recurrent toxicity from the responsible drug
• Incorrect diagnosis
• Sulfhemoglobinemia
• Inadequate response requiring specialist treatment

Toxicology consultation is particularly useful in refractory cases.

Alternative and Rescue Therapies

For severe methemoglobinemia when methylene blue is contraindicated or ineffective, specialist-directed options can include:

• Ascorbic acid
• Exchange transfusion
• Red-cell transfusion in selected circumstances
• Hyperbaric oxygen as an uncommon rescue strategy

Ascorbic acid reduces methemoglobin relatively slowly and is generally not a substitute for methylene blue in an immediately life-threatening case when methylene blue can safely be used.

Sulfhemoglobinemia

Sulfhemoglobinemia can closely resemble methemoglobinemia.

Features include:

• Persistent cyanosis
• Abnormal dyshemoglobin measurement
• Poor or absent response to methylene blue

Unlike methemoglobin, sulfhemoglobin cannot simply be enzymatically reduced back to normal hemoglobin.

Resolution therefore depends largely on replacement of affected erythrocytes over time.

Decontamination

For dermal exposure:

• Remove contaminated clothing.
• Wash exposed skin thoroughly.

For ingestion, gastrointestinal decontamination is not automatic.

Induced vomiting and routine gastric lavage are outdated approaches.

Activated charcoal may be considered for selected recent ingestions when:

• The causative substance is adsorbed,
• Clinically meaningful exposure occurred, and
• The airway is adequately protected.

Monitoring

Significant cases require:

• Continuous cardiac monitoring
• Respiratory monitoring
• Serial neurologic examinations
• Repeat MetHb measurements
• Assessment for recurrent toxicity

Recurrent measurements are particularly important after exposures such as dapsone, where methemoglobinemia can return after initial improvement.

Prognosis

Most acquired cases have an excellent outcome when:

• The oxidant exposure is stopped
• Tissue hypoxia is recognized promptly
• Appropriate treatment is provided

Severe untreated methemoglobinemia can cause:

• Myocardial ischemia
• Dysrhythmias
• Seizures
• Shock
• Coma
• Death

Key Points

• Methemoglobinemia results from oxidation of hemoglobin iron from Fe²⁺ to Fe³⁺.
• Methemoglobin cannot effectively carry oxygen and also causes a left shift of the remaining oxyhemoglobin dissociation curve.
• Classic causes include benzocaine, dapsone, nitrates/nitrites, aniline compounds, phenazopyridine, primaquine, and inhaled alkyl nitrites.
• Think of methemoglobinemia when there is cyanosis that does not improve as expected with oxygen.
• Blood may appear characteristically chocolate brown.
• Standard pulse oximetry is unreliable and often trends toward approximately 85%.
• PaO₂ can remain normal because it measures dissolved oxygen rather than hemoglobin oxygen-carrying capacity.
• Diagnosis is confirmed with co-oximetry.
• Methylene blue is the standard antidote for clinically significant acquired methemoglobinemia.
• Use methylene blue cautiously in G6PD deficiency, where it may be ineffective and can worsen hemolysis.
• Methylene blue also has MAO-A inhibitory activity and can interact with serotonergic medications.
• Dapsone can cause prolonged or recurrent methemoglobinemia, so continued monitoring may be necessary.
• Failure to respond to methylene blue should raise concern for continued oxidant exposure, G6PD deficiency, or sulfhemoglobinemia.